Inhibitors and methods of inhibiting bacterial and viral pathogens

ABSTRACT

Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to and benefit of U.S. ProvisionalApplication No. 61/306,102, filed Feb. 19, 2010, the contents of whichare hereby incorporated by reference in their entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

The research described herein was supported in part by funds from theU.S. Government Department of Defense contract HDTRA1-10-C-0036 and theU.S. Government may therefore have certain rights in the invention.

FIELD OF THE INVENTION

This invention relates to certain thiourea compounds, specificallyacylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivativesand analogs. This invention also relates to the use of these certainthiourea derivatives and analogs, as well as compositions containing thesame, for the treatment or prophylaxis of viral and bacterial infectionsas well as diseases associated thereof.

BACKGROUND OF THE INVENTION Flaviviridae

Dengue is a member of the Flaviviridae family which are enveloped,positive-sense RNA viruses whose human pathogens also include West Nilevirus (WNV), yellow fever virus (YFV), Japanese encephalitis virus(JEV), and tick-borne encephalitis virus (TBEV) among others. Denguetransmission is through the bite of an infected Aedes aegypti mosquitothat is found in tropical and sub-tropical regions around the world.Dengue fever (DF) is an acute febrile disease caused by one of fourclosely related virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Denguefever is classified based on its clinical characteristics into classicaldengue fever, or the more severe forms, dengue hemorrhagic feversyndrome (DHF), and dengue shock syndrome (DSS). Recovery from infectionfrom one serotype produces life-long immunity to that particularserotype, but provides only short-lived and limited protection againstany of the other serotypes.

Each year regional epidemics of dengue cause significant morbidity andmortality, social disruption and substantial economic burden on thesocieties affected both in terms of hospitalization and mosquitocontrol. Dengue is considered by the World Health Organization (WHO) tobe the most important arthropod-borne viral disease with an estimated 50million cases of dengue infection, including 500,000 DHF cases and24,000 deaths worldwide each year (36, 37). Dengue is also a CDC andNIAID Category A pathogen and in terms of bio-defense, represents asignificant threat to United States troops overseas. Preparedness forboth biodefense and for the public health challenges posed by denguewill require the development of new vaccines and antiviral therapeutics.

Orthomyxoviridae

The influenza virus is a member of the Orthomyxoviridae family. Eachyear regional epidemics of influenza cause significant morbidity andmortality, social disruption and substantial economic burden. During“flu season” it is estimated that influenza infects 10-20% of the USpopulation resulting in over 100,000 hospitalizations and 20,000 to40,000 deaths. The economic impact caused by influenza due to decreasedproductivity and increased health care utilization is estimated to be inthe billions of dollars.

Recent emergence of highly pathogenic avian influenza (H5N1) haselevated our fears of a possible human pandemic. The current circulatingH5N1 strain of virus is unusually pathogenic in birds causingdestruction of domestic and wild bird populations. In rare instances,the virus has infected humans causing mortality in almost 50% of cases.Should this virus acquire genetic traits that increase person to persontransmissibility widespread adverse public health and economic outcomeswould be expected. FDA-approved antiviral drugs are currently in use,but increasing resistance to existing countermeasures necessitates thedevelopment of new antiviral therapeutics with novel mechanisms ofaction against influenza.

Poxviridae

Orthopoxviruses are members of the Poxviridae family. Humanorthopoxviruses cause a spectrum of diseases ranging from severedisseminated lesional disease characteristic of the most common type ofvariola virus infection (variola major) to localized lesional infectioncaused by vaccinia virus. Of the several species of orthopoxvirus knownto infect humans, variola virus, the etiological agent of smallpox,causes far more serious infections than the other species of poxviruses.While variola virus no longer exists in the environment, otherorthopoxviruses continue to circulate and cause disease. Monkeypoxvirus, which is endemic in some areas of the Democratic Republic of theCongo, causes a zoonotic disease that is characterized by a generalizedinfection resembling a milder version of smallpox. Vaccinia-like viruseshave been isolated from patients in Brazil presenting with localizedlesions of the hands and arms and cowpox virus infections are increasingin certain parts of Europe. These viruses are believed to be maintainedin the population through rodent reservoirs and zoonotic disease isthought to arise from contact with infected animals, or through anintermediate species such as cattle or domestic pets. Disease severityin all cases is influenced by the status of the host immune system, withindividuals suffering from certain skin disorders or who areimmunocompromised developing the most severe infections. Preparednessfor both biodefense and for the public health challenges posed by humanorthopoxviruses requires the development of new antiviral therapeutics.

Togaviridae

Alphaviruses are members of the Togaviridae family. Alphaviruses cause aspectrum of human disease ranging from asymptomatic infection to severeencephalitis and death. The virus is transmitted by mosquito and ismaintained in the environment through an enzootic cycle involvinginfection of sylvatic hosts. Some alphaviruses achieve furtheramplification by exploiting domestic animals such as equines and pigs.Interest in alphaviruses has been renewed, because of reports thatcertain species of alphaviruses have been developed into efficient,stable biological weapons that are infectious by aerosol delivery andeasily produced in large quantities. No licensed vaccine or therapeuticexists to treat or prevent infection of pathogenic alphaviruses.Moreover, the antigenic diversity of this group of viruses presents aformidable challenge for vaccine development. Thus, therapeutics thattarget conserved replication functions of the virus serve as usefulcountermeasures for treatment of alphavirus disease.

Bunyaviridae

Based on recommendations by the CDC and the NIAID, viruses that might beused as biological weapons have been separated into three categories.Category A viruses are considered the most serious threat to nationalsecurity. These viruses have the greatest potential to cause widespreadillness and death in human populations. Category B viruses areconsidered biothreats due to the potential for weaponization of thesepathogens, and the projected high morbidity and mortality rates thatwould accompany their use as aerosolized agents. Category C virusesinclude emerging pathogens with the potential to be developed asbiowarfare agents or to otherwise pose a risk to public health andsafety. A national research and development effort has been undertakento develop a comprehensive biodefense strategy against these agents. Ofnote is the presence of four different members of the familyBunyaviridae among the viruses characterized as biothreats to the UnitedStates. This fact reflects the diverse worldwide impact of bunyavirusinfections on populations of livestock and humans. RVFV, a Category Abunyavirus, has been the cause of massive agricultural and socialhardship in Egypt and the Arabian peninsula. Infections of as many as200,000 people have been estimated in two epizootic epidemics resultingfrom RVFV transmission in 1977 and 1978, with an estimated 600associated fatalities. The second of the Category A bunyaviruses,hantavirus, has been the recognized cause of significant morbidity andmortality among military and civilian populations for over fifty years.U.S. troops suffered from chronic exposure to endemic hantavirus duringthe Korean conflict, and, more recently, hantavirus transmission fromrodent vectors to human populations has resulted in outbreaks of humandisease and death in the American southwest. CCHF, a Category Cpathogen, is a virus transmitted to humans who work in close contactwith livestock in geographic regions that extend from sub-Saharan Africato northern China. Infection with CCHF can lead to death in as many as30% of diagnosed individuals. CCHF has all of the characteristics of theCategory A viruses, except that current cell culture systems limitlarge-scale production capabilities; any technological advances in thisarea would elevate the risk posed by CCHF. The category B bunyavirus, LaCrosse encephalitis virus, is the leading cause of pediatricencephalitis in endemic regions of the) United States. To date, thereare no specific vaccines or antivirals approved for the treatment of theCategory A, B, or C bunyavirus infections in humans.

Arenaviridae

The arenaviruses are a diverse family of enveloped RNA viruses foundworldwide. These viruses generate high morbidity and mortality and canbe highly infectious by aerosol dissemination, promoting concern overtheir weaponization. Arenavirus infection in humans can lead to viralhemorrhagic fever, a serious illness characterized by extensive vasculardamage and bleeding diathesis, fever, and multiple organ involvement.Arenavirus infection in rodents, the natural host animal, is usuallychronic and asymptomatic. Five distinct arenaviruses cause severe HF inhumans and are classified as category A pathogens, defined as thosepathogens posing the greatest threat to public health and safety. Theseare Lassa fever, Machupo (causative agent of Bolivian HF), Junin(Argentine HF), Guanarito (Venezuelan HF), and Sabia, (Brazilian HF)viruses. Lassa fever is the most prominent biodefense target in thisgroup, due to its current prevalence (estimated at up to a half-millioncases annually, primarily in West Africa) and history of weaponizationresearch. Junin and Machupo viruses (endemic in South America) were alsoreportedly pursued as biological weapons by the former Soviet Union.Preparedness for both biodefense and for the public health challengesposed by human arenaviruses requires the development of new antiviraltherapeutics.

Filoviridae

Filoviruses including Ebola and Marburg viruses cause severe hemorrhagicdisease in humans resulting in high mortality. Infections result fromzoonotic transmission from an infected animal to humans. The naturalreservoirs and routes of transmission are not fully understood.Person-to-person transmission occurs primarily through physical contactwith infected material. No licensed vaccine or therapeutic exists totreat or prevent infection of filoviruses. Thus, therapeutics thattarget virus replication would serve as useful countermeasures fortreatment of filovirus disease.

Retroviridae

The HIV virus is a member if the retrovirus family. Currently, over 42million people are living with HIV/AIDS worldwide, and 74 percent ofthese infected people live in sub-Saharan Africa. By the year 2011, fivecountries (Ethiopia, Nigeria, China, India, and Russia) with 40 percentof the world's population will add 50 to 75 million infected people tothe worldwide pool of HIV disease. An estimated one million people arecurrently living with HIV in the United States, with approximately40,000 new infections occurring each year. FDA-approved antiviral drugsare currently in use, but increasing resistance to existingcountermeasures necessitates the development of new antiviraltherapeutics and treatment regimens/drug combinations to combat thislifelong infection.

Paramyxoviridae

Respiratory syncytial virus (RSV) is a nonsegmented, negative-strand RNAvirus in the Paramyxoviridae family. The RNA codes for ten viralproteins-three are associated with the nucleocapsid (NS1, NS2, N), threewith the envelope (SH, G, & F), two non-glycoslyated matrix proteins (Mand M2), a phosphoprotein (P), and a major polymerase subunit (L). RSVollness begins most frequently with fever, runny nose, cough, andsometimes wheezing. During their first RSV infection, between 25% and40% of infants and young children have signs or symptoms ofbronchiolitis or pneumonia, and 0.5% to 2% require hospitalization. Mostchildren recover from illness in 8 to 15 days. The majority of childrenhospitalized for RSV infection are under 6 months of age. RSV alsocauses repeated infections throughout life, usually associated withmoderate-to-severe cold-like symptoms; however, severe lower respiratorytract disease may occur at any age, especially among the elderly oramong those with compromised cardiac, pulmonary, or immune systems. RSVis spread from respiratory secretions through close contact withinfected persons or contact with contaminated surfaces or objects.Infection can occur when infectious material contacts mucous membranesof the eyes, mouth, or nose, and possibly through the inhalation ofdroplets generated by a sneeze or cough. In temperate climates, RSVinfections usually occur during annual community outbreaks, oftenlasting 4 to 6 months, during the late fall, winter, or early springmonths. The timing and severity of outbreaks in a community vary fromyear to year. RSV spreads efficiently among children during the annualoutbreaks, and most children will have serologic evidence of RSVinfection by 2 years of age.

RSV infects most children by age 2 and is the leading cause ofbronchiolitis and pneumonia in infants. It can also be a significantcause of disease in immunocompromised adults and the elderly. Estimatesvary on the actual number of cases, the most important of which arethose involving hospitalization. One report (CDC) estimates that up to126,300 children are hospitalized in the US each year. Another reportdescribes a more global view, which estimates that “a total of 18million people annually become infected by RSV in the US, Japan, France,Germany, Italy, Spain, UK, including three million adults withunderlying disease and almost 400,000 premature infants. Approximately900,000 of the individuals in these risk groups are hospitalized forthis infection each year.

Picornaviridae

Viruses in the family Picornaviridae replicate a positive sense,single-stranded genome and are transmitted as non-enveloped, infectiousvirions. Picornaviruses include the causative agents of such humandiseases as the common cold, Polio, Hand-Foot-and-Mouth Disease, andHepatitis A. These viruses are distributed across the globe, and along-term international eradication effort is currently underway tocontrol and eliminate poliovirus infection in humans. The significantrespiratory and enteric disease burden caused by these pathogensworldwide has led to numerous campaigns to identify antiviraltherapeutics and vaccines to combat picornavirus-associated diseases.Preparedness for the public health challenges posed by picornavirusesrequires the development of new antibacterial therapeutics.

Chlamydiaceae

Chlamydiae are obligate intracellular bacteria that cause seriousdiseases in humans and animals of veterinary significance. Sexuallytransmitted infections caused by C. trachomatis affect approximately 92million men and women worldwide, leading to a variety of pathologiesincluding urethritis, cervicitis, salpingitis, pelvic inflammatorydisease, ectopic pregnancy and infertility. The pathogen also causesblinding trachoma, which is the leading cause of preventable blindness,primarily in underdeveloped countries. Chlamydia pneumoniae is asignificant cause of respiratory infections, and there is evidence thatthese infections predispose individuals to atherosclerosis and perhapsother chronic conditions. Veterinary infections by a set of differentchlamydiae lead to epidemic in a diverse collection of species, and someof these can manifest as zoonoses in humans having contact with infectedanimals. Chlamydia psittaci, one such zoonotic agent, is considered apotential biothreat agent. Preparedness for both biodefense and for thepublic health challenges posed by C. burnetii requires the developmentof new antibacterial therapeutics.

Coxiellaceae

Coxiella burnetii is a zoonotic pathogen of ruminants that can beacquired by humans through contact with infected aerosols. C. burnettiis the etiologic agent of Q fever. Following an initial flu-likeillness, which occurs within 2-3 weeks of exposure to the bacteria, asubset of Q fever patients develop pneumonia or hepatitis. 1%-2% ofpeople with acute Q fever die of the disease. Acute infections can alsogive rise to chronic disease, which may lead to endocarditis and deathin infected individuals. C. burnetii is a highly infectious agent thatis rather resistant to heat and drying. It can become airborne andinhaled by humans. A single C. burnetii organism may cause disease in asusceptible person. This agent could be developed for use in biologicalwarfare and is considered a potential terrorist threat. Currenttreatment options for acute disease include doxycycline. For chronicdisease treatment, protocols combine doxycycline and quinolones.Preparedness for both biodefense and for the public health challengesposed by C. burnetii requires the development of new antibacterialtherapeutics.

SUMMARY OF THE INVENTION

The present invention provides a pharmaceutical composition comprising apharmaceutically acceptable carrier and a compound having the followinggeneral Formula I or a pharmaceutically acceptable salt thereof:

wherein R¹ is selected from the group consisting of: H, chloro, methyl,methoxy, ethoxy, nitro and fluoro;

R² is selected from the group consisting of: H, chloro, methyl, methoxy,trifluoromethyl, propanoylamino and 2-methylpropanoylamino;

R³ is selected from the group consisting of: H, methyl, amino,methylamino, dimethylamino, phenylamino and 3-pyridylamino;

R⁴ is selected from the group consisting of: H, chloro, methyl, methoxy,trifluoromethyl and trifluoromethoxy; and

R⁵ is selected from the group consisting of H and methyl.

The present invention also provides a method for the treatment orprophylaxis of a viral or bacterial infection or disease associatedtherewith, comprising administering in a therapeutically effectiveamount to a mammal in need thereof, a compound of Formula I below or apharmaceutically acceptable salt thereof:

wherein R¹ is selected from the group consisting of: H, chloro, methyl,methoxy, ethoxy, nitro and fluoro;

R² is selected from the group consisting of: H, chloro, methyl, methoxy,trifluoromethyl, propanoylamino and 2-methylpropanoylamino;

R³ is selected from the group consisting of: H, methyl, amino,methylamino, dimethylamino, phenylamino and 3-pyridylamino;

R⁴ is selected from the group consisting of: H, chloro, methyl, methoxy,trifluoromethyl and trifluoromethoxy; and

R⁵ is selected from the group consisting of H and methyl.

The present invention further provides a compound selected from thegroup consisting of:N-[(4-amino-3-methoxy-phenyl)carbamothioyl]-4-tert-butyl-benzamide;N-[(4-amino-2-chloro-phenyl)carbamothioyl]-4-tert-butyl-benzamidehydrochloride;4-tert-butyl-N-[[2-chloro-4-(methylamino)phenyl]-carbamothioyl]benzamidehydrochloride;4-tert-butyl-N-[(2-chloro-5-methyl-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(2-chloro-6-methyl-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[[2-chloro-3-(trifluoromethyl)phenyl]-carbamothioyl]benzamide;N-[(4-amino-3-methoxy-phenyl)carbamothioyl]-4-tert-butyl-benzamidehydrochloride;4-tert-butyl-N-[(2-chloro-3-methyl-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[[4-(methylamino)phenyl]-carbamothioyl]benzamidehydrochloride;4-tert-butyl-N-[[2-chloro-4-(dimethylamino)phenyl]-carbamothioyl]benzamidehydrochloride;4-tert-butyl-N-[[2-chloro-5-(trifluoromethoxy)phenyl]-carbamothioyl]benzamide;and 4-tert-butyl-N-[[4-(3-pyridylamino)phenyl]-carbamothioyl]benzamidehydrochloride.

The present invention also provides a pharmaceutical compositioncomprising a pharmaceutically acceptable carrier and a compound havingthe following general Formula II or a pharmaceutically acceptable saltthereof:

wherein X is selected from the group consisting of oxygen and NH;

Y is selected from the group consisting of: —CH₂—, —C(═O)—, —C(═S)— and—C(═NH)—;

A is selected from the group consisting of: N and CR⁵;

B is selected from the group consisting of: N and CR⁶;

R¹ is selected from the group consisting of: hydrogen and ethyl;

R² is selected from the group consisting of: hydrogen and chloro;

R³ is selected from the group consisting of: hydrogen, methoxy, aminoand hydroxyl;

R⁴ is selected from the group consisting of: hydrogen, chloro and amino;

R⁵ is selected from the group consisting of hydrogen and aminomethyl;and

R⁶ is selected from the group consisting of hydrogen, amino andaminomethyl.

The present invention further provides a method for the treatment orprophylaxis of a viral or bacterial infection or disease associatedtherewith, comprising administering in a therapeutically effectiveamount to a mammal in need thereof, a compound of Formula II below or apharmaceutically acceptable salt thereof:

wherein X is selected from the group consisting of oxygen and NH;

Y is selected from the group consisting of: —CH₂—, —C(═O)—, —C(═S)— and—C(═NH)—;

A is selected from the group consisting of: N and CR⁵;

B is selected from the group consisting of: N and CR⁶;

R¹ is selected from the group consisting of: hydrogen and ethyl;

R² is selected from the group consisting of: hydrogen and chloro;

R³ is selected from the group consisting of: hydrogen, methoxy, aminoand hydroxyl;

R⁴ is selected from the group consisting of: hydrogen, chloro and amino;

R⁵ is selected from the group consisting of hydrogen and aminomethyl;and

R⁶ is selected from the group consisting of hydrogen, amino andaminomethyl.

The present invention also provides a compound selected from the groupconsisting of:N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-hydroxy-phenyl]-2-chloro-benzamide;4-tert-butyl-N-[[4-[(2-chlorophenyl)-methylamino]-3-methoxy-phenyl]-carbamothioyl]-benzamide;N-[2-amino-4-[(4-tert-butylbenzoyl)-carbamothioylamino]-phenyl]-2-chloro-benzamidehydrochloride;N-[(4-benzamido-2-chloro-phenyl)carbamothioyl]-4-tert-butyl-benzamide;4-tert-butyl-N-[[4-[(2-chlorobenzene-carbothioyl)amino]-3-methoxy-phenyl]-carbamothioyl]benzamide;4-(aminomethyl)-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamidehydrochloride;N-[4-[(4-tert-butylbenzene-carboximidoyl)-carbamothioylamino]-2-methoxy-phenyl]-2-chloro-benzamide;4-tert-butyl-N-[[4-[(2-chlorobenzene-carboximidoyl)amino]-3-methoxy-phenyl]-carbamothioyl]benzamide;3-(aminomethyl)-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamidehydrochloride;2-amino-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamide;N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]pyridine-3-carboxamide;N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]pyridine-4-carboxamide;N-[[4-[(4-aminobenzoyl)amino]-3-methoxy-phenyl]-carbamothioyl]-4-tert-butyl-benzamidehydrochloride; andN-[4-[(4-tert-butylbenzoyl)-carbamothioyl-ethyl-amino]-2-methoxy-phenyl]-2-chloro-benzamide.

The present invention further provides a pharmaceutical compositioncomprising a pharmaceutically acceptable carrier and a compound havingthe following general Formula III or a pharmaceutically acceptable saltthereof:

wherein Y is absent or is selected from the group consisting of: —CH₂—,—C(═O)—, —C(═S)— and —C(═NH)—;

R¹ is selected from the group consisting of aryl, cycloalkane and alkyl;

R² is alkyl; and

R³ is selected from the group consisting of: aryl, cycloalkane andalkyl.

The present invention also provides a method for the treatment orprophylaxis of a viral or bacterial infection or disease associatedtherewith, comprising administering in a therapeutically effectiveamount to a mammal in need thereof, a compound of Formula III below or apharmaceutically acceptable salt thereof:

wherein Y is absent or is selected from the group consisting of: —CH₂—,—C(═O)—, —C(═S)— and —C(═NH)—;

R¹ is selected from the group consisting of aryl, cycloalkane and alkyl;

R² is alkyl; and

R³ is selected from the group consisting of: aryl, cycloalkane andalkyl.

The present invention further provides a compound having the followinggeneral Formula III or a pharmaceutically acceptable salt thereof:

wherein Y is absent or is selected from the group consisting of: —CH₂—,—C(═O)—, —C(═S)— and —C(═NH)—;

R¹ is selected from the group consisting of aryl, cycloalkane and alkyl;

R² is alkyl; and

R³ is selected from the group consisting of: aryl, cycloalkane andalkyl.

The present invention also provides a pharmaceutical compositioncomprising a pharmaceutically acceptable carrier and a compound selectedfrom the group consisting of:4-tert-butyl-N-[[4-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]-3-methoxy-phenyl]-carbamothioyl]benzamide;N-[(3-aminophenyl)-carbamothioyl]-4-tert-butyl-benzamide;N-[(4-acetamido-3-methoxy-phenyl)-carbamothioyl]-4-tert-butyl-benzamide;4-tert-butyl-N-[[3-methoxy-4-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)-pentanoylamino]phenyl]-carbamothioyl]benzamide;2-chloro-N-[4-(cyclohexanecarbonyl-carbamothioylamino)-2-methoxy-phenyl]benzamide;2-chloro-N-[4-(ethylcarbamo-thioylamino)-2-methoxy-phenyl]benzamide;methyl3-[4-[(4-tert-butylbenzoyl)carbamo-thioylamino]-2-methoxy-anilino]-3-oxo-propanoate;4-tert-butyl-N-[(3-methoxy-4-ureido-phenyl)carbamothioyl]-benzamide;4-tert-butyl-N-[[4-(4-pyridylamino)phenyl]-carbamothioyl]benzamidehydrochloride;N-[[4-[(4-tert-butylbenzoyl)amino]phenyl]carbamothioyl]-4-methyl-benzamide;4-tert-butyl-N-[(5-tert-butyl-2-hydroxy-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-(cyclohexyl-carbamothioyl)benzamide;4-tert-butyl-N-[(4-methoxyphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(4-nitrophenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(3-cyano-4,5-dimethyl-2-thienyl)-carbamothioyl]benzamide;4-tert-butyl-N-(ethylcarbamothioyl)-benzamide; andN-[3-[(4-tert-butylbenzoyl)-carbamothioylamino]phenyl]-2-chloro-benzamide.

The present invention further provides a method for the treatment orprophylaxis of a viral or bacterial infection or disease associatedtherewith, comprising administering in a therapeutically effectiveamount to a mammal in need thereof, a compound selected from the groupconsisting of:4-tert-butyl-N-[[4-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]-3-methoxy-phenyl]-carbamothioyl]benzamide;N-[(3-aminophenyl)-carbamothioyl]-4-tert-butyl-benzamide;N-[(4-acetamido-3-methoxy-phenyl)-carbamothioyl]-4-tert-butyl-benzamide;4-tert-butyl-N-[[3-methoxy-4-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)-pentanoylamino]phenyl]-carbamothioyl]benzamide;2-chloro-N-[4-(cyclohexanecarbonyl-carbamothioylamino)-2-methoxy-phenyl]benzamide;2-chloro-N-[4-(ethylcarbamo-thioylamino)-2-methoxy-phenyl]benzamide;methyl3-[4-[(4-tert-butylbenzoyl)carbamo-thioylamino]-2-methoxy-anilino]-3-oxo-propanoate;4-tert-butyl-N-[(3-methoxy-4-ureido-phenyl)carbamothioyl]-benzamide;4-tert-butyl-N-[[4-(4-pyridylamino)phenyl]-carbamothioyl]benzamidehydrochloride;N-[[4-[(4-tert-butylbenzoyl)amino]phenyl]carbamothioyl]-4-methyl-benzamide;4-tert-butyl-N-[(5-tert-butyl-2-hydroxy-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-(cyclohexyl-carbamothioyl)benzamide;4-tert-butyl-N-[(4-methoxyphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(4-nitrophenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(3-cyano-4,5-dimethyl-2-thienyl)-carbamothioyl]benzamide;4-tert-butyl-N-(ethylcarbamothioyl)-benzamide; andN-[3-[(4-tert-butylbenzoyl)-carbamothioylamino]phenyl]-2-chloro-benzamide.

The present invention also provides a compound selected from the groupconsisting of:4-tert-butyl-N-[[4-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]-3-methoxy-phenyl]-carbamothioyl]benzamide;N-[(3-aminophenyl)-carbamothioyl]-4-tert-butyl-benzamide;N-[(4-acetamido-3-methoxy-phenyl)-carbamothioyl]-4-tert-butyl-benzamide;4-tert-butyl-N-[[3-methoxy-4-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)-pentanoylamino]phenyl]-carbamothioyl]benzamide;2-chloro-N-[4-(cyclohexanecarbonyl-carbamothioylamino)-2-methoxy-phenyl]benzamide;2-chloro-N-[4-(ethylcarbamo-thioylamino)-2-methoxy-phenyl]benzamide;methyl3-[4-[(4-tert-butylbenzoyl)carbamo-thioylamino]-2-methoxy-anilino]-3-oxo-propanoate;4-tert-butyl-N-[(3-methoxy-4-ureido-phenyl)carbamothioyl]-benzamide; and4-tert-butyl-N-[[4-(4-pyridylamino)phenyl]-carbamothioyl]benzamidehydrochloride.

Other objects and advantages of the present invention will becomeapparent from the following description and appended claims.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the invention include compounds which are of thefollowing general Formula I or a pharmaceutically acceptable saltthereof:

wherein R¹ is selected from the group consisting of: H, chloro, methyl,methoxy, ethoxy, nitro and fluoro;

R² is selected from the group consisting of: H, chloro, methyl, methoxy,trifluoromethyl, propanoylamino and 2-methylpropanoylamino;

R³ is selected from the group consisting of: H, methyl, amino,methylamino, dimethylamino, phenylamino and 3-pyridylamino;

R⁴ is selected from the group consisting of: H, chloro, methyl, methoxy,trifluoromethyl and trifluoromethoxy; and

R⁵ is selected from the group consisting of H and methyl.

Preferably, R¹ is hydrogen or chloro; R² is hydrogen or trifluoromethyl;R³ is amino or methylamino; R⁴ is hydrogen or methoxy; and R⁵ ishydrogen.

Preferably, the compound of Formula I of the present is selected fromthe group consisting of:N-[(4-amino-3-methoxy-phenyl)carbamothioyl]-4-tert-butyl-benzamide;N-[(4-amino-2-chloro-phenyl)carbamothioyl]-4-tert-butyl-benzamidehydrochloride;4-tert-butyl-N-[[2-chloro-4-(methylamino)phenyl]-carbamothioyl]benzamidehydrochloride;4-tert-butyl-N-[(2-chloro-5-methyl-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(2-chloro-6-methyl-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[[2-chloro-3-(trifluoromethyl)phenyl]-carbamothioyl]benzamide;N-[(4-amino-3-methoxy-phenyl)carbamothioyl]-4-tert-butyl-benzamidehydrochloride;4-tert-butyl-N-[(2-chloro-3-methyl-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[[4-(methylamino)phenyl]-carbamothioyl]benzamidehydrochloride;4-tert-butyl-N-[[2-chloro-4-(dimethylamino)phenyl]-carbamothioyl]benzamidehydrochloride;4-tert-butyl-N-[[2-chloro-5-(trifluoromethoxy)phenyl]-carbamothioyl]benzamide;4-tert-butyl-N-[[4-(3-pyridylamino)phenyl]-carbamothioyl]benzamidehydrochloride; 4-tert-butyl-N-[(2-chlorophenyl)carbamothioyl]-benzamide;4-tert-butyl-N-(o-tolylcarbamothioyl)-benzamide;4-tert-butyl-N-[[2-chloro-5-(trifluoromethyl)phenyl]-carbamothioyl]benzamide;N-[(4-anilinophenyl)-carbamothioyl]-4-tert-butyl-benzamide;4-tert-butyl-N-[(3-chloro-2-methyl-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(2,4-dimethylphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(4-dimethylaminophenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(2,5-dichlorophenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(2-methoxyphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(3-chlorophenyl)-carbamothioyl]benzamide;4-tert-butyl-N-(phenylcarbamothioyl)-benzamide;4-tert-butyl-N-[(2,3-dimethylphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(3,4-dimethylphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(2-ethoxyphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[[3-(2-methylpropanoylamino)-phenyl]carbamothioyl]-benzamide;4-tert-butyl-N-[(2-nitrophenyl)carbamothioyl]-benzamide;4-tert-butyl-N-(p-tolylcarbamothioyl)-benzamide;N-[(4-aminophenyl)-carbamothioyl]-4-tert-butyl-benzamide;4-tert-butyl-N-[(2-fluorophenyl)carbamothioyl]-benzamide;4-tert-butyl-N-[[3-(propanoylamino)phenyl]-carbamothioyl]benzamide;4-tert-butyl-N-(m-tolylcarbamothioyl)-benzamide;4-tert-butyl-N-[(3,5-dimethylphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(3-methoxyphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(2,5-dimethylphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(4-dimethylaminophenyl)-carbamothioyl]benzamidehydrochloride; and4-tert-butyl-N-[(2,6-dimethylphenyl)-carbamothioyl]benzamide.

More preferably, the compound of Formula I4-tert-butyl-N-[(2-chloro-5-methyl-phenyl)-carbamothioyl]benzamide.

TABLE 1 List of certain novel compounds of Formula I of the presentinvention. Com- pound Chemical Structure Molecular Formula AnalyticalData Chemical Name  1

C19H23N3O2S 1H NMR in DMSO-d6: δ 12.53 (s, 1H), 11.26 (s, 1H), 7.94 (d,2H), 7.56 (d, 2H), 7.25 (d, 1H), 6.96 (dd, 1H), 6.63 (d, 1H), 4.83 (s,2H), 3.77 (s, 3H), 1.32 (s, 9H); Mass Spec: 358.1 (M + H)⁺N-[(4-amino-3-methoxy- phenyl)carbamothioyl]-4- tert-butyl-benzamide  4

C18H20ClN3OS HCl 1H NMR in DMSO-d6: δ 12.42 (s, 1H), 11.52 (s, 1H), 7.95(d, 2H), 7.55-7.63 (m, 3H), 6.84 (br, 1H), 6.69 (br, 1H), 1.32 (s, 9H);Mass Spec: 361.9 (M + H)⁺; 384.0 (M + Na)⁺ N-[(4-amino-2-chloro-phenyl)carbamothioyl]-4- tert-butyl-benzamide hydrochloride  5

C19H22ClN3OS HCl 1H NMR in DMSO-d6: δ 12.41 (s, 1H), 11.50 (s, 1H), 7.95(d, 2H), 7.60 (d, 1H), 7.56 (d, 2H), 6.66 (d, 1H), 6.56 (dd, 1H), 2.70(s, 3H), 1.32 (s, 9H); Mass Spec: 375.9 (M + H)⁺; 397.9 (M + Na)⁺4-tert-butyl-N-[[2-chloro- 4-(methylamino)phenyl]-carbamothioyl]benzamide hydrochloride 11

C19H21ClN2OS 1H NMR in DMSO-d6: δ 12.69 (s, 1H), 11.65 (s, 1H), 7.97 (d,2H), 7.87 (s, 1H), 7.57 (d, 2H), 7.46 (d, 1H), 7.15 (dd, 1H), 2.33 (s,3H), 1.33 (s, 9H); Mass Spec: 361.0 (M + H)⁺; 382.8 (M + Na)⁺4-tert-butyl-N-[(2-chloro- 5-methyl-phenyl)- carbamothioyl]benzamide 13

C19H21ClN2OS 1H NMR in DMSO-d6: δ 12.05 (s, 1H), 11.63 (s, 1H), 7.99 (d,2H), 7.57 (d, 2H), 7.37-7.42 (m, 1H), 7.25-7.31 (m, 2H), 2.27 (s, 3H),1.33 (s, 9H); Mass Spec: 360.9 (M + H)⁺; 382.9 (M + Na)⁺4-tert-butyl-N-[(2-chloro- 6-methyl-phenyl)- carbamothioyl]benzamide 15

C19H18ClF3N2OS 1H NMR in DMSO-d6: δ 12.67 (s, 1H), 11.80 (s, 1H), 8.17(d, 1H), 7.98 (d, 2H), 7.83 (d, 1H), 7.63 (t, 1H), 7.58 (d, 2H), 1.33(s, 9H); Mass Spec: 414.7 (M + H)⁺ 4-tert-butyl-N-[[2-chloro- 3-(trifluoromethyl)phenyl]- carbamothioyl]benzamide 18

C19H23N3O2S HCl 1H NMR in DMSO-d6: δ 12.70 (s, 1H), 11.50 (s, 1H), 7.95(d, 2H), 7.62 (s, 1H), 7.57 (d, 2H), 7.29-7.38 (m, 2H), 3.89 (s, 3H),1.32 (s, 9H); Mass Spec: 358.0 (M + H)⁺; 380.0 (M + Na)⁺N-[(4-amino-3-methoxy- phenyl)carbamothioyl]-4- tert-butyl-benzamidehydrochloride 19

C19H21ClN2OS 1H NMR in DMSO-d6: δ 12.73 (s, 1H), 11.65 (s, 1H), 7.97 (d,2H), 7.87 (t, 1H), 7.57 (d, 2H), 7.31 (d, 2H), 2.40 (s, 3H), 1.33 (s,9H); Mass Spec: 361.0 (M + H)⁺; 383.0 (M + Na)⁺4-tert-butyl-N-[(2-chloro- 3-methyl-phenyl)- carbamothioyl]benzamide 21

C19H23N3OS HCl 1H NMR in DMSO-d6: δ 12.52 (s, 1H), 11.34 (s, 1H), 7.94(d, 2H), 7.56 (d, 2H), 7.5l (d, 2H), 6.85 (br, 2H), 2.77 (s, 3H), 1.32(s, 9H); Mass Spec: 342.0 (M + H)⁺; 364.0 (M + Na)⁺ 4-tert-butyl-N-[[4-(methylamino)phenyl]- carbamothioyl]benzamide hydrochloride 22

C20H24ClN3OS HCl 1H NMR in DMSO-d6: δ 12.48 (s, 1H), 11.52 (s, 1H), 7.96(d, 2H), 7.72 (d, 1H), 7.56 (d, 2H), 6.80 (d, 1H), 6.73 (dd, 1H), 2.94(s, 6H), 1.32 (s, 9H); Mass Spec: 390.0 (M + H)⁺; 411.9 (M + Na)⁺4-tert-butyl-N-[[2-chloro- 4- (dimethylamino)phenyl]-carbamothioyl]benzamide hydrochloride 29

C19H18ClF3N2O2S 1H NMR in DMSO-d6: δ 12.95 (br, 1H), 11.81 (br, 1H),8.34 (d, 1H), 7.97 (d, 2H), 7.75 (d, 1H), 7.58 (d, 2H), 7.37 (dd, 1H),1.33 (s, 9H) 4-tert-butyl-N-[[2-chloro- 5- (trifluoromethoxy)phenyl]-carbamothioyl]benzamide 36

C23H24N4OS HCl 1H NMR in DMSO-d6: δ 12.64 (s, 1H), 11.43 (s, 1H), 9.81(br, 1H), 8.46 (d, 1H), 8.22 (d, 1H), 8.09 (dd, 1H), 7.96 (d, 2H), 7.78(dd, 1H), 7.70 (d, 2H), 7.57 (d, 2H), 7.32 (d, 2H), 1.32 (s, 9H); MassSpec: 405.1 (M + H)⁺; 427.1 (M + Na)⁺ 4-tert-butyl-N-[[4-(3-pyridylamino)phenyl]- carbamothioyl]benzamide hydrochloride

TABLE 2 List of certain compounds of Formula I of the present invention.Compound Chemical Structure Molecular Formula Chemical Name 40

C18H19ClN2OS 4-tert-butyl-N-[(2- chlorophenyl)carbamothioyl]-benzamide42

C19H22N2OS 4-tert-butyl-N-(o-tolylcarbamothioyl)- benzamide 44

C19H18ClF3N2OS 4-tert-butyl-N-[[2-chloro-5- (trifluoromethyl)phenyl]-carbamothioyl]benzamide 45

C24H25N3OS N-[(4-anilinophenyl)-carbamothioyl]-4- tert-butyl-benzamide47

C19H21ClN2OS 4-tert-butyl-N-[(3-chloro-2-methyl-phenyl)-carbamothioyl]benzamide 48

C20H24N2OS 4-tert-butyl-N-[(2,4-dimethylphenyl)- carbamothioyl]benzamide49

C20H25N3OS 4-tert-butyl-N-[(4-dimethylaminophenyl)-carbamothioyl]benzamide 50

C18H18Cl2N2OS 4-tert-butyl-N-[(2,5-dichlorophenyl)-carbamothioyl]benzamide 51

C19H22N2O2S 4-tert-butyl-N-[(2-methoxyphenyl)- carbamothioyl]benzamide52

C18H19ClN2OS 4-tert-butyl-N-[(3-chlorophenyl)- carbamothioyl]benzamide53

C18H20N2OS 4-tert-butyl-N-(phenylcarbamothioyl)- benzamide 54

C20H24N2OS 4-tert-butyl-N-[(2,3-dimethylphenyl)- carbamothioyl]benzamide55

C20H24N2OS 4-tert-butyl-N-[(3,4-dimethylphenyl)- carbamothioyl]benzamide56

C20H24N2O2S 4-tert-butyl-N-[(2-ethoxyphenyl)- carbamothioyl]benzamide 57

C22H27N3O2S 4-tert-butyl-N-[[3-(2- methylpropanoylamino)-phenyl]carbamothioyl]-benzamide 58

C18H19N3O3S 4-tert-butyl-N-[(2- nitrophenyl)carbamothioyl]-benzamide 59

C19H22N2OS 4-tert-butyl-N-(p-tolylcarbamothioyl)- benzamide 60

C18H21N3OS N-[(4-aminophenyl)-carbamothioyl]-4- tert-butyl-benzamide 61

C18H19FN2OS 4-tert-butyl-N-[(2- fluorophenyl)carbamothioyl]-benzamide 62

C21H25N3O2S 4-tert-butyl-N-[[3- (propanoylamino)phenyl]-carbamothioyl]benzamide 63

C19H22N2OS 4-tert-butyl-N-(m-tolylcarbamothioyl)- benzamide 65

C20H24N2OS 4-tert-butyl-N-[(3,5-dimethylphenyl)- carbamothioyl]benzamide66

C19H22N2O2S 4-tert-butyl-N-[(3-methoxyphenyl)- carbamothioyl]benzamide67

C20H24N2OS 4-tert-butyl-N-[(2,5-dimethylphenyl)- carbamothioyl]benzamide70

C20H25N3OS HCl 4-tert-butyl-N-[(4-dimethylaminophenyl)-carbamothioyl]benzamide hydrochloride 71

C20H24N2OS 4-tert-butyl-N-[(2,6-dimethylphenyl)- carbamothioyl]benzamide

The compounds of the invention include compounds which are of thefollowing general Formula II or a pharmaceutically acceptable saltthereof:

wherein X is selected from the group consisting of oxygen and NH;

Y is selected from the group consisting of: —CH₂—, —C(═O)—, —C(═S)— and—C(═NH)—;

A is selected from the group consisting of: N and CR⁵;

B is selected from the group consisting of: N and CR⁶;

R¹ is selected from the group consisting of: hydrogen and ethyl;

R² is selected from the group consisting of: hydrogen and chloro;

R³ is selected from the group consisting of: hydrogen, methoxy, aminoand hydroxyl;

R⁴ is selected from the group consisting of: hydrogen, chloro and amino;

R⁵ is selected from the group consisting of hydrogen and aminomethyl;and

R⁶ is selected from the group consisting of hydrogen, amino andaminomethyl.

Preferably, X is oxygen; Y is —CH₂— or —C(═O)—; A is C—H; B is C—H; R¹is hydrogen; R² is hydrogen; R³ is methoxy; R⁴ is chloro; and each of R⁵and R⁶ is hydrogen.

Preferably, the compound of Formula II is selected from the groupconsisting of:N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-hydroxy-phenyl]-2-chloro-benzamide;4-tert-butyl-N-[[4-[(2-chlorophenyl)-methylamino]-3-methoxy-phenyl]-carbamothioyl]-benzamide;N-[2-amino-4-[(4-tert-butylbenzoyl)-carbamothioylamino]-phenyl]-2-chloro-benzamidehydrochloride;N-[(4-benzamido-2-chloro-phenyl)carbamothioyl]-4-tert-butyl-benzamide;4-tert-butyl-N-[[4-[(2-chlorobenzene-carbothioyl)amino]-3-methoxy-phenyl]-carbamothioyl]benzamide;4-(aminomethyl)-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamidehydrochloride;N-[4-[(4-tert-butylbenzene-carboximidoyl)-carbamothioylamino]-2-methoxy-phenyl]-2-chloro-benzamide;4-tert-butyl-N-[[4-[(2-chlorobenzene-carboximidoyl)amino]-3-methoxy-phenyl]-carbamothioyl]benzamide;3-(aminomethyl)-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamidehydrochloride;2-amino-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamide;N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]pyridine-3-carboxamide;N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]pyridine-4-carboxamide;N-[[4-[(4-aminobenzoyl)amino]-3-methoxy-phenyl]-carbamothioyl]-4-tert-butyl-benzamidehydrochloride;N-[4-[(4-tert-butylbenzoyl)-carbamothioyl-ethyl-amino]-2-methoxy-phenyl]-2-chloro-benzamide;N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]-2-chloro-benzamide;and N-[(4-benzamidophenyl)-carbamothioyl]-4-tert-butyl-benzamide.

More preferably, the compound of Formula II isN-[2-amino-4-[(4-tert-butylbenzoyl)-carbamothioylamino]-phenyl]-2-chloro-benzamidehydrochloride.

TABLE 3 List of certain novel compounds of Formula II of the presentinvention. Com- Molecular pound Chemical Structure Formula AnalyticalData Chemical Name  2

C25H24ClN3O3S 1H NMR in DMSO-d6: δ 12.68 (s, 1H), 11.44 (s, 1H), 10.08(s, 1H), 9.67 (s, 1H), 7.96 (d, 2H), 7.82 (d, 1H), 7.63 (dd, 1H),7.54-7.59 (m, 3H), 7.43- 7.52 (m, 3H), 7.08 (dd, 1H), 1.33 (s, 9H)N-[4-[(4-tert-butylbenzoyl)- carbamothioylamino]-2-hydroxy-phenyl]-2-chloro- benzamide  3

C26H28ClN3O2S 1H NMR in DMSO-d6: δ 12.52 (s, 1H), 11.27 (s, 1H), 7.93(d, 2H), 7.55 (d, 2H), 7.45-7.7.47 (m, 1H), 7.23-7.37 (m, 4H), 6.98 (dd,1H), 6.28 (d, 1H), 5.79 (t, 1H), 4.41 (d, 2H), 3.84 (s, 3H), 1.32 (s,9H); Mass Spec: 481.9 (M + H)⁺ 4-tert-butyl-N-[[4-[(2- chlorophenyl)-methylamino]-3-methoxy- phenyl]-carbamothioyl]- benzamide  6

C25H25ClN4O2S HCl 1H NMR in DMSO-d6: δ 12.63 (s, 1H), 11.38 (s, 1H),9.85 (s, 1H), 7.95 (d, 2H), 7.68 (dd, 1H), 7.57 (d, 3H), 7.45-7.53 (m,2H), 7.36 (d, 1H), 7.26 (s, 1H), 7.00 (dd, 1H), 3.68 (br, 3H), 1.33 (s,9H); Mass Spec: 481.0 (M + H)⁺; 503.0 (M + Na)⁺ N-[2-amino-4-[(4-tert-butylbenzoyl)- carbamothioylamino]- phenyl]-2-chloro-benzamidehydrochloride  7

C25H24ClN3O2S 1H NMR in DMSO-d6: 12.65 (s, 1H), 11.67 (s, 1H), 10.48 (s,1H), 8.12 (d, 1H), 7.96-7.99 (m, 5H), 7.76 (dd, 1H), 7.53- 7.64 (m, 5H),1.33 (s, 9H); Mass Spec: 466.2 (M + H)⁺; 488.1 (M + Na)⁺N-[(4-benzamido-2-chloro- phenyl)carbamothioyl]-4- tert-butyl-benzamide 8

C26H26ClN3O2S2 1H NMR in Pyridine-d5: δ 13.41 (s, 1H), 12.97 (s, 1H),12.44 (s, 1H), 8.70 (d, 1H), 8.02-8.10 (m, 3H), 7.77 (dd, 1H), 7.63 (dd,1H), 7.50 (d, 2H), 7.30 (dd, 1H), 7.08-7.26 (m, 2H), 3.70 (s, 3H), 1.24(s, 9H); 13C NMR in CDCl3: δ 177.80, 166.88, 164.10, 157.90, 148.08,135.35, 133.83, 131.63, 130.83, 130.48, 130.44, 4-tert-butyl-N-[[4-[(2-chlorobenzene- carbothioyl)amino]-3- methoxy-phenyl)-carbamothioyl]benzamide 128.62, 127.43, 127.23, 126.28, 126.06, 119.86,116.26, 106.40, 56.15, 35.28, 31.04; Mass Spec: 512.0 (M + H)⁺; 534.0(M + Na)⁺ 12

C27H30N4O3S HCl 1H NMR in DMSO-d6: δ 12.74 (s, 1H), 11.47 (s, 1H), 9.54(s, 1H), 8.40 (br, 3H), 8.02 (d, 2H), 7.96 (d, 2H), 7.77 (d, 1H), 7.62(d, 3H), 7.58 (d, 2H), 7.31 (dd, 1H), 4.13 (q, 2H), 3.86 (s, 3H), 1.33(s, 9H); Mass Spec: 491.0 (M + H)⁺; 513.0 (M + Na)⁺4-(aminomethyl)-N-[4-[(4- tert-butylbenzoyl)- carbamothioylamino]-2-methoxy-phenyl]benzamide hydrochloride 23

C26H27ClN4O2S 1H NMR in TFA-d1: δ 8.60 (br, 1H), 8.04 (s, 6H), 7.73-7.82(m, 5H), 7.40 (br, 2H), 4.25 (s, 3H), 1.68 (s, 9H); Mass Spec: 495.1(M + H)⁺; 517.1 (M + Na)⁺ N-[4-[(4-tert-butylbenzene- carboximidoyl)-carbamothioylamino]-2- methoxy-phenyl]-2-chloro- benzamide 24

C26H27ClN4O2S 1H NMR in DMSO-d6: δ 12.67 (br, 1H), 10.13 (br, 1H), 9.66(br, 1H), 8.24 (s, 1H), 7.93 (d, 2H), 7.56 (d, 2H), 7.25-7.49 (m, 5H),6.74 (br, 1H), 3.71 (s, 3H), 1.32 (s, 9H); Mass Spec: 495.0 (M + H)⁺4-tert-butyl-N-[[4-[(2- chlorobenzene- carboximidoyl)amino]-3-methoxy-phenyl]- carbamothioyl]benzamide 27

C27H30N4O3S HCl 1H NMR in DMSO-d6: δ 12.74 (s, 1H), 11.48 (br, 1H), 9.51(s, 1H), 8.25 (br, 3H), 8.09 (s, 1H), 8.01 (d, 1H), 7.97 (d, 2H), 7.78(d, 1H), 7.68 (d, 1H), 7.57- 7.61 (m, 4H), 7.31 (dd, 1H), 4.14 (s, 2H),3.86 (s, 3H), 1.33 (s, 9H); Mass Spec: 491.0 (M + H)⁺; 513.0 (M + Na)⁺3-(aminomethyl)-N-[4-[(4- tert-butylbenzoyl)- carbamothioylamino)-2-methoxy-phenyl]benzamide hydrochloride 28

C26H28N4O3S 1H NMR in DMSO-d6: δ 12.73 (br, 1H), 11.45 (br, 1H), 9.22(s, 1H), 7.96 (d, 2H), 7.79 (d, 1H), 7.65 (dd, 1H), 7.57 (d, 3H), 7.27(dd, 1H), 7.21 (td, 1H), 6.76 (dd, 1H), 6.59 (td, 1H), 6.38 (s, 2H),3.85 (s, 3H), 1.33 (s, 9H); Mass Spec: 477.0 (M + H)⁺; 499.0 (M + Na)⁺2-amino-N-[4-[(4-tert- butylbenzoyl)- carbamothioylamino]-2-methoxy-phenyl]benzamide 30

C25H26N4O3S 1H NMR in DMSO-d6: δ 12.75 (s, 1H), 11.47 (s, 1H), 9.80 (s,1H), 9.11 (d, 1H), 8.76 (dd, 1H), 8.30 (dt, 1H), 7.97 (d, 2H), 7.74 (d,1H), 7.62 (d, 1H), 7.55-7.60 (3H), 7.31 (dd, 1H), 3.85 (s, 3H), 1.33 (s,9H); Mass Spec: 463.0 (M + H)⁺; 485.0 (M + Na)⁺N-[4-[(4-tert-butylbenzoyl)- carbamothioylamino]-2-methoxy-phenyl]pyridine-3- carboxamide 31

C25H26N4O3S 1H NMR in CDCl3: δ 12.78 (s, 1H), 9.05 (s, 1H), 8.82 (d,2H), 8.55 (d, 2H), 7 86 (d, 1H), 7.84 (d, 2H), 7.73 (dd, 2H), 7.57 (d,2H), 7.16 (dd, 1H), 3.99 (s, 3H), 1.37 (s, 9H); Mass Spec: 463.0 (M +H)⁺; 484.9 (M + Na)⁺ N-[4-[(4-tert-butylbenzoyl)- carbamothioylamino]-2-methoxy-phenyl]pyridine-4- carboxamide 32

C26H28N4O3S HCl 1H NMR in DMSO-d6: δ 12.72 (s, 1H), 11.44 (s, 1H), 9.00(s, 1H), 7.96 (d, 2H), 7.88 (d, 1H), 7.73 (d, 2H), 7.56-7.58 (m, 3H),7.25 (dd, 1H), 6.71 (d, 2H), 3.86 (s, 3H), 1.33 (s, 9H); Mass Spec:477.0 (M + H)⁺; 499.0 (M + Na)⁺ N-[[4-[(4- aminobenzoyl)amino]-3-methoxy-phenyl]- carbamothioyl]-4-tert-butyl- benzamide hydrochloride 34

C28H30ClN3O3S 1H NMR in DMSO-d6: δ 10.50 (s, 1H), 9.60 (s, 1H), 7.95 (d,1H), 7.38- 7.63 (m, 8H), 6.99 (s, 1H), 6.89 (d, 1H), 4.28 (br, 2H), 3.80(s, 3H), 1.25 (s, 9H), 1.21 (t, 3H); Mass Spec: 524.0 (M + H)⁺; 546.0(M + Na)⁺ N-[4-[(4-tert-butylbenzoyl)- carbamothioyl-ethyl-amino]-2-methoxy-phenyl]-2-chloro- benzamide

TABLE 4 List of certain compounds of Formula II of the presentinvention. Compound Chemical Structure Molecular Formula Chemical Name39

C26H26ClN3O3S N-[4-[(4-tert-butylbenzoyl)- carbamothioylamino]-2-methoxy-phenyl]-2- chloro-benzamide 43

C25H25N3O2S N-[(4-benzamidophenyl)- carbamothioyl]-4-tert-butyl-benzamide

The compounds of the invention include compounds which are of thefollowing general Formula III or a pharmaceutically acceptable saltthereof:

wherein Y is absent or is selected from the group consisting of: —CH₂—,—C(═O)—, —C(═S)— and —C(═NH)—;

R¹ is selected from the group consisting of aryl, cycloalkane and alkyl;

R² is alkyl; and

R³ is selected from the group consisting of: aryl, cycloalkane andalkyl.

Preferably, Y is —C(═O)—; R¹ is an aryl more preferably R¹ is selectedfrom the group consisting of: substituted monocyclic, unsubstitutedmonocyclic, unsubstituted polycyclic and heteroaryl, most preferably R¹is a substituted monocyclic aryl ring; R² is an alkyl selected from thegroup consisting of: C₁-C₆ branched alkyl, unbranched alkyl, substitutedalkyl and unsubstituted alkyl, more preferably R² is an unbranchedalkyl; R³ is an aryl selected from the group consisting of: substitutedaryl, unsubstituted monocyclic aryl, unsubstituted polycyclic aryl andheteroaryl, more preferably, R³ is C₃-C₇ cycloalkane, C₁-C₄ branched orunbranched alkyl or a substituted aryl.

Preferably, the compound of Formula III is selected from the groupconsisting of:(NZ)-4-tert-butyl-N-[(2-chloro-5-methyl-anilino)-ethylsulfanyl-methylene]benzamide;N-[4-[[(Z)—N-(4-tert-butylbenzoyl)-C-ethylsulfanyl-carbonimidoyl]amino]-2-methoxy-phenyl]-2-chloro-benzamide;and(NZ)-4-tert-butyl-N-[(2-chloroanilino)-ethylsulfanyl-methylene]benzamide.

More preferably, the compound of Formula III is(NZ)-4-tert-butyl-N-[(2-chloro-5-methyl-anilino)-ethylsulfanyl-methylene]benzamide.

TABLE 5 List of certain novel compounds of Formula III of the presentinvention. Compound Chemical Structure Molecular Formula Analytical DataChemical Name  9

C21H25ClN2OS 1H NMR in CDCl3: δ 12.67 (s, 1H), 8.23 (br, 2H), 7.47 (d,2H), 7.33-7.36 (m, 2H), 7.08 (br, 1H), 3.24 (q, 2H), 1.42 (t, 3H), 1.36(s, 9H); Mass Spec: 388.9 (M + H)⁺; 410.8 (M + Na)⁺(NZ)-4-tert-butyl-N-[(2- chloro-5-methyl-anilino)- ethylsulfanyl-methylene]benzamide 10

C28H30ClN3O3S 1H NMR in DMSO-d6: δ 11.41 (br, 1H), 9.69 (s, 1H), 8.05(d, 2H), 7.94 (d, 1H), 7.41-7.61 (m, 6H), 7.23 (br, 1H), 7.08 (br, 1H),3.79 (s, 3H), 3.08-3.17 (m, 2H), 1.25- 1.35 (m, 12H); Mass Spec: 524.0(M + H)⁺; 545.9 (M + Na)⁺ N-[4-[[(Z)-N-(4-tert- butylbenzoyl)-C-ethylsulfanyl- carbonimidoyl]amino]-2- methoxy-phenyl]-2-chloro-benzamide 14

C20H23ClN2OS 1H NMR in DMSO-d6: δ 11.69 (br, 1/2H), 10.43 (br, 1/2H),8.05 (br, 1H), 7.32- 7.72 (m, 5H), 7.20 (br, 1H), 6.98 (br, 1H),2.96-3.18 (m, 2H), 1.28-1.34 (m, 12H); Note: NH proton most likelyswitching between the 2 positions and reason for 2 signals at 11.69 and10.43 ppm: Mass Spec: 375.0 (M + H)⁺; 397.0 (M + Na)⁺(NZ)-4-tert-butyl-N-[(2- chloroanilino)-ethylsulfanyl-methylene]benzamide

The compounds of the invention also include each of the followingcompounds:4-tert-butyl-N-[[4-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]-3-methoxy-phenyl]-carbamothioyl]benzamide;N-[(3-aminophenyl)-carbamothioyl]-4-tert-butyl-benzamide;N-[(4-acetamido-3-methoxy-phenyl)-carbamothioyl]-4-tert-butyl-benzamide;4-tert-butyl-N-[[3-methoxy-4-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)-pentanoylamino]phenyl]-carbamothioyl]benzamide;2-chloro-N-[4-(cyclohexanecarbonyl-carbamothioylamino)-2-methoxy-phenyl]benzamide;2-chloro-N-[4-(ethylcarbamo-thioylamino)-2-methoxy-phenyl]benzamide;methyl3-[4-[(4-tert-butylbenzoyl)carbamo-thioylamino]-2-methoxy-anilino]-3-oxo-propanoate;4-tert-butyl-N-[(3-methoxy-4-ureido-phenyl)carbamothioyl]-benzamide;4-tert-butyl-N-[[4-(4-pyridylamino)phenyl]-carbamothioyl]benzamidehydrochloride;N-[[4-[(4-tert-butylbenzoyl)amino]phenyl]carbamothioyl]-4-methyl-benzamide;4-tert-butyl-N-[(5-tert-butyl-2-hydroxy-phenyl)-carbamothioyl]benzamide;4-tert-butyl-N-(cyclohexyl-carbamothioyl)benzamide;4-tert-butyl-N-[(4-methoxyphenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(4-nitrophenyl)-carbamothioyl]benzamide;4-tert-butyl-N-[(3-cyano-4,5-dimethyl-2-thienyl)-carbamothioyl]benzamide;4-tert-butyl-N-(ethylcarbamothioyl)-benzamide; andN-[3-[(4-tert-butylbenzoyl)-carbamothioylamino]phenyl]-2-chloro-benzamide.Preferably, the compound is4-tert-butyl-N-[[4-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]-3-methoxy-phenyl]-carbamothioyl]benzamide.A preferred compound isN-[(4-acetamido-3-methoxy-phenyl)-carbamothioyl]-4-tert-butyl-benzamide.

TABLE 6 List of certain novel compounds of the present invention. Com-Molecular pound Chemical Structure Formula Analytical Data Chemical Name16

C31H34N4O4S2 1H NMR in CDCl3: δ 12.63 (s, 1H) 8.98 (s, 1H), 8.49 (d,1H), 8.36 (d, 1H), 8.17 (d, 1H), 7.79 (d, 2H), 7.53-7.58 (m, 3H), 7.43-7.47 (m, 3H), 7.18 (d, 1H), 6.98-7.02 (m, 1H), 3.41 (s, 3H), 2.87 (s,6H), 1.35 (s, 9H) 4-tert-butyl-N- [[4-[[5- (dimethylamino)- 1-naphthyl]sulfonylamino]-3- methoxy-phenyl]- carbamothioyl] benzamide 17

C18H21N3OS 1H NMR in CDCl₃: δ 12.57 (s, 1H), 9.00 (s, 1H), 7.82 (d, 2H),7.55 (d, 2H), 7.27- 7.28 (m, 1H), 7.19 (t, 1H), 7.03 (dd, 1H), 6.63 (dd,1H), 1.36 (s, 9H); Mass Spec: 328.1 (M + H)⁺ N-[(3- aminophenyl)-carbamothioyl]- 4-tert-butyl- benzamide 20

C21H25N3O3S 1H NMR in DMSO-d6: δ 12.69 (s, 1H), 11.42 (s, 1H), 9.19 (s,1H), 7.92-7.96 (m, 3H), 7.54-7.58 (m, 3H), 7.19 (dd, 1H), 3.84 (s, 3H),2.09 (s, 3H), 1.32 (s, 9H); Mass Spec: 400.0 (M + H)⁺; 422.0 (M + Na)⁺N-[(4-acetamido- 3-methoxy- phenyl)- carbamothioyl]- 4-tert-butyl-benzamide 25

C29H37N5O4S2 1H NMR in CDCl3: δ 12.69 (s, 1H), 9.06 (s, 1H), 8.41 (d,1H), 7.83 (d, 2H), 7.79 (s, 1H), 7.73 (s, 1H), 7.56 (d, 2H), 7.08 (d,1H), 4.81 (s, 1H), 4.54 (s, 1H), 4.34 (m, 1H), 3.93 (s, 3H), 3.68 (s,1H), 3.19 (br, 1H), 2.93 (m, 1H), 2.74 (d, 1H), 2.44 (m, 2H) 1.45-1.81(m, 6H), 1.36 (s, 9H) 4-tert-butyl-N- [[3-methoxy-4- [5-(2-oxo-1,3,3a,4,6,6a- hexahydrothieno [3,4-d]imidazol- 4-yl)- pentanoylamino]phenyl]- carbamothioyl] benzamide 26

C22H24ClN3O3S 1H NMR in CDCl3: δ 12.50 (s, 1H), 8.57 (d, 1H), 8.57 (s,1H), 8.52 (s, 1H), 7.78 (dd, 1H), 7.72 (d, 1H), 7.35-7.48 (m, 3H), 7.08(dd, 1H), 3.90 (s, 3H), 2.24 (tt, 1H), 1.92-2.00 (m, 2H), 1.83-1.89 (m,2H), 1.69- 1.76 (m, 1H), 1.45-1.57 (m, 2H), 1.20-1.38 (3H); Mass Spec:446.0 (M + H)⁺; 467.9 (M + Na)⁺ 2-chloro-N-[4- (cyclo- hexanecarbonyl-carbamothioyl- amino)- 2-methoxy- phenyl]benzamide 33

C17H18ClN3O2S 1H NMR in CDCl3: δ 8.60 (d, 1H), 8.58 (s, 1H), 7.79 (dd,1H), 7.56 (br, 1H), 7.38-7.49 (m, 3H), 6.90 (dd, 1H), 6.77 (d, 1H), 6.01(br, 1H), 3.89 (s, 3H), 3.68 (q, 2H), 1.20 (t, 3H); Mass Spec: 363.9(M + H)⁺; 386.0 (M + Na)⁺ 2-chloro-N-[4- (ethylcarbamo- thioylamino)-2-methoxy- phenyl] benzamide 35

C23H27N3O5S 1H NMR in DMSO-d6: δ 12.70 (s, 1H), 11.43 (s, 1H), 9.58 (s,1H), 7.94-8.03 (m, 3H), 7.56-7.58 (m, 3H), 7.21 (d, 1H), 3.86 (s, 3H),3.66 (s, 3H), 3.62 (s, 2H), 1.32 (s, 9H); Mass Spec: 458.0 (M + H)⁺;480.0 (M + Na)⁺ methyl 3-[4- [(4-tert- butylbenzoyl) carbamo-thioylamino]- 2-methoxy- anilino]-3-oxo- propanoate 37

C20H24N4O3S 1H NMR in DMSO-d6: δ 12.65 (br, 1H), 11.37 (br, 1H), 8.09(d, 1H), 8.00 (s, 1H), 7.95 (d, 2H), 7.56 (d, 2H), 7.50 (d, 1H), 7.10(dd, 1H), 6.21 (s, 2H), 3.85 (s, 3H), 1.32 (s, 9H); Mass Spec: 401.0(M + H)⁺; 423.0 (M + Na)⁺ 4-tert-butyl-N- [(3-methoxy-4- ureido-phenyl)carbamothioyl]- benzamide 38

C23H24N4OS HCl 1H NMR in DMSO-d6: δ 12.76 (s, 1H), 11.58 (s, 1H), 8.52(s, 2H), 8.49 (d, 2H), 7.95-7.99 (m, 4H), 7.72 (d, 2H), 7.58 (d, 2H),6.98 (d, 2H), 1.33 (s, 9H), Mass Spec: 405.1 (M + H)⁺ 4-tert-butyl-N-[[4-(4- pyridylamino) phenyl]- carbamothioyl] benzamide hydrochloride

TABLE 7 List of certain compounds of the present invention. CompoundChemical Structure Molecular Formula Chemical Name 41

C26H27N3O2S N-[[4-[(4-tert- butylbenzoyl)amino]phenyl]carbamothioyl]-4-methyl-benzamide 46

C22H28N2O2S 4-tert-butyl-N-[(5-tert-butyl-2-hydroxy-phenyl)-carbamothioyl]benzamide 64

C18H26N2OS 4-tert-butyl-N-(cyclohexyl- carbamothioyl)benzamide 68

C19H22N2O2S 4-tert-butyl-N-[(4-methoxyphenyl)- carbamothioyl]benzamide69

C18H19N3O3S 4-tert-butyl-N-[(4-nitrophenyl)- carbamothioyl]benzamide 72

C19H21N3OS2 4-tert-butyl-N-[(3-cyano-4,5-dimethyl-2-thienyl)-carbamothioyl]benzamide 73

C14H20N2OS 4-tert-butyl-N-(ethylcarbamothioyl)-benzamide 74C25H24ClN3O2S N-[3-[(4-tert-butylbenzoyl)-carbamothioylamino]phenyl]-2-chloro- benzamide

The method of the present invention is for the treatment or prophylaxisof a viral or bacterial infection or disease associated therewith,comprising administering in a therapeutically effective amount to amammal in need thereof, any of the compounds described above.

Preferably, the mammal is a human. Also preferably, the viral infectionis caused by a virus family selected from the group consisting of:Bunyaviridae, Poxviridae, Arenaviridae, Picornaviridae, Togaviridae,Flaviviridae, Filoviridae, Paramyxoviridae, Orthomyxoviridae andRetroviridae.

In one embodiment of the invention, the viral infection is aBunyaviridae infection preferably caused by a virus selected from thegroup consisting of Rift Valley fever virus, La Crosse virus and Andesvirus.

In another embodiment of the invention, the viral infection is aPoxviridae infection preferably caused by a virus selected from thegroup consisting of the vaccinia virus and monkeypox virus.

In yet another embodiment of the invention, the viral infection is anArenaviridae infection preferably caused by a virus selected from thegroup consisting of Tacaribe virus and lymphocytic choriomeningitisvirus.

In another embodiment of the invention, the viral infection ds aPicornaviridae infection preferably caused by Encephalomyocarditisvirus.

In yet another embodiment of the invention, the viral infection is aTogaviridae infection preferably caused by Sindbis virus.

In yet another embodiment of the invention, the viral infection is aFlaviviridae infection preferably caused by a virus selected from thegroup consisting of Dengue virus, West Nile virus, yellow fever virus,Japanese encephalitis virus, and tick-borne encephalitis virus. Mostpreferably, the flavivirus is a Dengue virus selected from the groupconsisting of DEN-1, DEN-2, DEN-3, and DEN-4. In yet another embodimentof the invention, the viral infection is associated with a conditionselected from the group consisting of Dengue fever, Yellow fever, WestNile, St. Louis encephalitis, Hepatitis C, Murray Valley encephalitis,and Japanese encephalitis. Most preferably, the viral infection isassociated with Dengue fever wherein said Dengue fever is selected fromthe group consisting of classical dengue fever, dengue hemorrhagic feversyndrome, and dengue shock syndrome.

In yet another embodiment of the invention, the viral infection is aFiloviridae infection preferably caused by a virus selected from thegroup consisting of Ebola virus and Zaire strain.

In yet another embodiment of the invention, the viral infection is anOrthomyxoviridae infection preferably caused by an influenza virus,preferably the H1N1 virus.

In yet another embodiment of the invention, the viral infection iscaused by a Retroviridae infection preferably caused by a HumanImmunodeficiency virus.

The method of the present invention may also comprise co-administrationof: a) other antivirals such as Ribavirin or cidofovir; b) vaccines;and/or c) interferons or pegylated interferons.

Preferably, the bactaerial infection is caused by a bacteria familyselected from the group consisting of Chlamydiaceae and Coxiellaceae.

In one embodiment, the bacterial infection is a Chlamydiaceae infectionpreferably caused by bacteria selected from the group consisting ofChlamydophila caviae and Chlamydophila muridarum.

In another embodiment of the invention, the bacterial infection is aCoxiellaceae infection preferably caused by Coxiella burnetti bacteria.

TABLE 8 Pathogen families and human diseases associated therewith. HumanDisease Associated Pathogen Family with Pathogen Family BunyaviridaeHemorrhagic fever, retinal vasculitis, encephalitis, hemorrhagic feverwith renal syndrome (HFRS), hantavirus pulmonary syndrome(HPS)Poxviridae Family members include causative agents of smallpox andmonkeypox. Arenaviridae Hemorrhagic fever Picornaviridae Common cold,Poliovirus, Hand- Foot-and-Mouth Disease, Hepatitis A. TogaviridaeEncephalitis, arthritic disease, Rubella Flaviviridae Dengue hemorrhagicfever, Dengue shock syndrome Filoviridae Hemorrhagic feverParamyxoviridae Mumps, measles, pneumonia, bronchitis OrthomyxoviridaeInfluenza Retroviridae AIDS, cancer Chlamydiaceae Chlamydia CoxiellaceaeQ fever

DEFINITIONS

In accordance with this detailed description, the followingabbreviations and definitions apply. It must be noted that as usedherein, the singular forms “a,” “an,” and “the” include plural referentsunless the context clearly dictates otherwise.

The publications discussed herein are provided solely for theirdisclosure. Nothing herein is to be construed as an admission regardingantedating the publications. Further, the dates of publication providedmay be different from the actual publication dates, which may need to beindependently confirmed.

Where a range of values is provided, it is understood that eachintervening value is encompassed. The upper and lower limits of thesesmaller ranges may independently be included in the smaller, subject toany specifically-excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either bothof those included limits are also included in the invention. Alsocontemplated are any values that fall within the cited ranges.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art. Any methods and materials similar or equivalent to thosedescribed herein can also be used in practice or testing. Allpublications mentioned herein are incorporated herein by reference todisclose and describe the methods and/or materials in connection withwhich the publications are cited.

By “patient” or “subject” is meant to include any mammal. A “mammal,”for purposes of treatment, refers to any animal classified as a mammal,including but not limited to, humans, experimental animals includingrats, mice, and guinea pigs, domestic and farm animals, and zoo, sports,or pet animals, such as dogs, horses, cats, cows, and the like.

The term “efficacy” as used herein refers to the effectiveness of aparticular treatment regime. Efficacy can be measured based on change ofthe course of the disease in response to an agent.

The term “success” as used herein in the context of a chronic treatmentregime refers to the effectiveness of a particular treatment regime.This includes a balance of efficacy, toxicity (e.g., side effects andpatient tolerance of a formulation or dosage unit)′, patient compliance,and the like. For a chronic administration regime to be considered“successful” it must balance different aspects of patient care andefficacy to produce a favorable patient outcome.

The terms “treating,” “treatment,” and the like are used herein to referto obtaining a desired pharmacological and physiological effect. Theeffect may be prophylactic in terms of preventing or partiallypreventing a disease, symptom, or condition thereof and/or may betherapeutic in terms of a partial or complete cure of a disease,condition, symptom, or adverse effect attributed to the disease. Theterm “treatment,” as used herein, covers any treatment of a disease in amammal, such as a human, and includes: (a) preventing the disease fromoccurring in a subject which may be predisposed to the disease but hasnot yet been diagnosed as having it, i.e., causing the clinical symptomsof the disease not to develop in a subject that may be predisposed tothe disease but does not yet experience or display symptoms of thedisease; (b) inhibiting the disease, i.e., arresting or reducing thedevelopment of the disease or its clinical symptoms; and (c) relievingthe disease, i.e., causing regression of the disease and/or its symptomsor conditions. Treating a patient's suffering from disease related topathological inflammation is contemplated. Preventing, inhibiting, orrelieving adverse effects attributed to pathological inflammation overlong periods of time and/or are such caused by the physiologicalresponses to inappropriate inflammation present in a biological systemover long periods of time are also contemplated.

As used herein, “acyl” refers to the groups H—C(O)—, alkyl-C(O)—,substituted alkyl-C(O)—, alkenyl-C(O)—, substituted alkenyl-C(O)—,alkynyl-C(O)—, substituted alkynyl-C(O)—, cycloalkyl-C(O)—, substitutedcycloalkyl-C(O)—, aryl-C(O)—, substituted aryl-C(O)—, heteroaryl-C(O)—,substituted heteroaryl-C(O)—, heterocyclic-C(O)—, and substitutedheterocyclic-C(O)— wherein alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein.

“Alkylamino” refers to the group —NRR where each R is independentlyselected from the group consisting of hydrogen, alkyl, substitutedalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl,substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl,substituted heteroaryl, heterocyclic, substituted heterocyclic and whereeach R is joined to form together with the nitrogen atom a heterocyclicor substituted heterocyclic ring wherein alkyl, substituted alkyl,alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein.

“Alkenyl” refers to alkenyl group preferably having from 2 to 10 carbonatoms and more preferably 2 to 6 carbon atoms and having at least 1 andpreferably from 1-2 sites of alkenyl unsaturation.

“Alkoxy” refers to the group “alkyl-O—” which includes, by way ofexample, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy,sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.

“Alkyl” refers to linear or branched alkyl groups having from 1 to 10carbon atoms, alternatively 1 to 6 carbon atoms. This term isexemplified by groups such as methyl, t-butyl, n-heptyl, octyl and thelike.

“Amino” refers to the group —NH₂.

“Aryl” or “Ar” refers to an unsaturated aromatic carbocyclic group offrom 6 to 14 carbon atoms having a single ring (e.g., phenyl) ormultiple condensed rings (e.g., naphthyl or anthryl) which condensedrings may or may not be aromatic (e.g., 2-benzoxazolinone,2H-1,4-benzoxazin-3(4H)-one, and the like) provided that the point ofattachment is through an aromatic ring atom.

“Substituted aryl” refers to aryl groups which are substituted with from1 to 3 substituents selected from the group consisting of hydroxy, acyl,acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy,substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl,aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, aryl,substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substitutedcycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy,substituted heterocyclyloxy, carboxyl, carboxylalkyl,carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substitutedcycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl,carboxyl-substituted heteroaryl, carboxylheterocyclic,carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol,thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl,thioheteroaryl, substituted thioheteroaryl, thiocycloalkyl, substitutedthiocycloalkyl, thioheterocyclic, substituted thioheterocyclic,cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, halo,nitro, heteroaryl, substituted heteroaryl, heterocyclic, substitutedheterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy,substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy,oxycarbonylamino, oxythiocarbonylamino, —S(O)₂-alkyl, —S(O)₂-substitutedalkyl, —S(O)₂-cycloalkyl, —S(O)₂-substituted cycloalkyl, —S(O)₂-alkenyl,—S(O)₂-substituted alkenyl, —S(O)₂-aryl, —S(O)₂-substituted aryl,—S(O)₂-heteroaryl, —S(O)₂-substituted heteroaryl, —S(O)₂-heterocyclic,—S(O)₂-substituted heterocyclic, —OS(O)₂-alkyl, —OS(O)₂-substitutedalkyl, —OS(O)₂-aryl, —OS(O)₂-substituted aryl, —OS(O)₂-heteroaryl,—OS(O)₂-substituted heteroaryl, —OS(O)₂-heterocyclic,—OS(O)₂-substituted heterocyclic, —OS(O)₂—NRR where R is hydrogen oralkyl, —NRS(O)₂-alkyl, —NRS(O)₂-substituted alkyl, —NRS(O)₂-aryl,—NRS(O)₂-substituted aryl, —NRS(O)₂-heteroaryl, —NRS(O)₂-substitutedheteroaryl, —NRS(O)₂-heterocyclic, —NRS(O)₂-substituted heterocyclic,—NRS(O)₂—NR-alkyl, —NRS(O)₂—NR-substituted alkyl, —NRS(O)₂—NR-aryl,—NRS(O)₂—NR-substituted aryl, —NRS(O)₂—NR-heteroaryl,—NRS(O)₂—NR-substituted heteroaryl, —NRS(O)₂—NR-heterocyclic,—NRS(O)₂—NR-substituted heterocyclic where R is hydrogen or alkyl, mono-and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- anddi-arylamino, mono- and di-substituted arylamino, mono- anddi-heteroarylamino, mono- and di-substituted heteroarylamino, mono- anddiheterocyclic amino, mono- and di-substituted heterocyclic amino,unsymmetric di-substituted amines having different substituentsindependently selected from the group consisting of alkyl, substitutedalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic and amino groups on thesubstituted aryl blocked by conventional blocking groups such as Boc,Cbz, formyl, and the like or substituted with —SO₂NRR where R ishydrogen or alkyl.

“Cycloalkyl” refers to cyclic alkyl groups of from 3 to 8 carbon atomshaving a single cyclic ring including, by way of example, cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl and the like. Excludedfrom this definition are multi-ring alkyl groups such as adamantanyl,etc.

“Halo” or “halogen” refers to fluoro, chloro, bromo and iodo.

“Heteroaryl” refers to an aromatic carbocyclic group of from 2 to 10carbon atoms and 1 to 4 heteroatoms selected from the group consistingof oxygen, nitrogen and sulfur within the ring or oxides thereof. Suchheteroaryl groups can have a single ring (e.g., pyridyl or furyl) ormultiple condensed rings (e.g., indolizinyl or benzothienyl) wherein oneor more of the condensed rings may or may not be aromatic provided thatthe point of attachment is through an aromatic ring atom. Additionally,the heteroatoms of the heteroaryl group may be oxidized, i.e., to formpyridine N-oxides or 1,1-dioxo-1,2,5-thiadiazoles and the like.Additionally, the carbon atoms of the ring may be substituted with anoxo (═O). The term “heteroaryl having two nitrogen atoms in theheteroaryl, ring” refers to a heteroaryl group having two, and only two,nitrogen atoms in the heteroaryl ring and optionally containing 1 or 2other heteroatoms in the heteroaryl ring, such as oxygen or sulfur.

“Substituted heteroaryl” refers to heteroaryl groups which aresubstituted with from 1 to 3 substituents selected from the groupconsisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy,alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, amidino,alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy,aminocarbonylamino, aminothiocarbonylamino, aryl, substituted aryl,aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy,heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substitutedheterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl,carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl,carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substitutedheteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic,carboxylamido, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl,substituted thioaryl, thioheteroaryl, substituted thioheteroaryl,thiocycloalkyl, substituted thiocycloalkyl, thioheterocyclic,substituted thioheterocyclic, cycloalkyl, substituted cycloalkyl,guanidino, guanidinosulfone, halo, nitro, heteroaryl, substitutedheteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy,substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy,heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino,oxythiocarbonylamino, —S(O)₂-alkyl, —S(O)₂-substituted alkyl,—S(O)₂-cycloalkyl, —S(O)₂-substituted cycloalkyl, —S(O)₂-alkenyl,—S(O)₂-substituted alkenyl, —S(O)₂-aryl, —S(O)₂-substituted aryl,—S(O)₂-heteroaryl, —S(O)₂-substituted heteroaryl, —S(O)₂-heterocyclic,—S(O)₂-substituted heterocyclic, —OS(O)₂-alkyl, —OS(O)₂-substitutedalkyl, —OS(O)₂-aryl, —OS(O)₂-substituted aryl, —OS(O)₂-heteroaryl,—OS(O)₂-substituted heteroaryl, —OS(O)₂-heterocyclic,—OS(O)₂-substituted heterocyclic, —OSO₂—NRR where R is hydrogen oralkyl, —NRS(O)₂-alkyl, —NRS(O)₂-substituted alkyl, —NRS(O)₂-aryl,—NRS(O)₂-substituted aryl, —NRS(O)₂-heteroaryl, —NRS(O)₂-substitutedheteroaryl, —NRS(O)₂-heterocyclic, —NRS(O)₂-substituted heterocyclic,—NRS(O)₂—NR-alkyl, —NRS(O)₂—NR-substituted alkyl, —NRS(O)₂—NR-aryl,—NRS(O)₂—NR— substituted aryl, —NRS(O)₂—NR-heteroaryl, —NRS(O)₂—NR—substituted heteroaryl, —NRS(O)₂—NR-heterocyclic,—NRS(O)₂—NR-substituted heterocyclic where R is hydrogen or alkyl, mono-and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- anddi-arylamino, mono- and di-substituted arylamino, mono- anddi-heteroarylamino, mono- and di-substituted heteroarylamino, mono- anddiheterocyclic amino, mono- and di-substituted heterocyclic amino,unsymmetric di-substituted amines having different substituentsindependently selected from the group consisting of alkyl, substitutedalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclic and substituted heterocyclic and amino groups on thesubstituted aryl blocked by conventional blocking groups such as Boc,Cbz, formyl, and the like or substituted with —SO₂NRR where R ishydrogen or alkyl.

“Sulfonyl” refers to the group —S(P)₂R where R is selected from thegroup consisting of hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, substitutedaryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substitutedheteroaryl, heterocyclic, substituted heterocyclic wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl,heteroaryl, substituted heteroaryl, heterocyclic and substitutedheterocyclic are as defined herein.

“Optionally substituted” means that the recited group may beunsubstituted or the recited group may be substituted.

“Pharmaceutically-acceptable carrier” means a carrier that is useful inpreparing a pharmaceutical composition or formulation that is generallysafe, non-toxic, and neither biologically nor otherwise undesirable, andincludes a carrier that is acceptable for veterinary use as well ashuman pharmaceutical use.

“Pharmaceutically-acceptable cation” refers to the cation of apharmaceutically-acceptable salt.

“Pharmaceutically-acceptable salt” refers to salts which retain thebiological effectiveness and properties of compounds which are notbiologically or otherwise undesirable. Pharmaceutically-acceptable saltsrefer to pharmaceutically-acceptable salts of the compounds, which saltsare derived from a variety of organic and inorganic counter ions wellknown in the art and include, by way of example only, sodium, potassium,calcium, magnesium, ammonium, tetraalkylammonium, and the like; and whenthe molecule contains a basic functionality, salts of organic orinorganic acids, such as hydrochloride, hydrobromide, tartrate,mesylate, acetate, maleate, oxalate and the like.

Pharmaceutically-acceptable base addition salts can be prepared frominorganic and organic bases. Salts derived from inorganic bases include,by way of example only, sodium, potassium, lithium, ammonium, calciumand magnesium salts. Salts derived from organic bases include, but arenot limited to, salts of primary, secondary and tertiary amines, such asalkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines,di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenylamines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines,di(substituted alkenyl) amines, tri(substituted alkenyl) amines,cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines,substituted cycloalkyl amines, disubstituted cycloalkyl amine,trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkenyl)amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines,disubstituted cycloalkenyl amine, trisubstituted cycloalkenyl amines,aryl amines, diaryl amines, triaryl amines, heteroaryl amines,diheteroaryl amines, triheteroaryl amines, heterocyclic amines,diheterocyclic amines, triheterocyclic amines, mixed di- and tri-amineswhere at least two of the substituents on the amine are different andare selected from the group consisting of alkyl, substituted alkyl,alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl,cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic,and the like. Also included are amines where the two or threesubstituents, together with the amino nitrogen, form a heterocyclic orheteroaryl group.

Examples of suitable amines include, by way of example only,isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine,tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine,lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline,betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine,purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and thelike. It should also be understood that other carboxylic acidderivatives would be useful, for example, carboxylic acid amides,including carboxamides, lower alkyl carboxamides, dialkyl carboxamides,and the like.

Pharmaceutically-acceptable acid addition salts may be prepared frominorganic and organic acids. Salts derived from inorganic acids includehydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like. Salts derived from organic acids includeacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid,malic acid, malonic acid, succinic acid, maleic acid, fumaric acid,tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid,salicylic acid, and the like.

A compound may act as a pro-drug. Pro-drug means any compound whichreleases an active parent drug in vivo when such pro-drug isadministered to a mammalian subject. Pro-drugs are prepared by modifyingfunctional groups present in such a way that the modifications may becleaved in vivo to release the parent compound. Pro-drugs includecompounds wherein a hydroxy, amino, or sulfhydryl group is bonded to anygroup that may be cleaved in vivo to regenerate the free hydroxyl,amino, or sulfhydryl group, respectively. Examples of pro-drugs include,but are not limited to esters (e.g., acetate, formate, and benzoatederivatives), carbamates (e.g., N,N-dimethylamino-carbonyl) of hydroxyfunctional groups, and the like.

“Treating” or “treatment” of a disease includes:

(1) preventing the disease, i.e. causing the clinical symptoms of thedisease not to develop in a mammal that may be exposed to or predisposedto the disease but does not yet experience or display symptoms of thedisease,(2) inhibiting the disease, i.e., arresting or reducing the developmentof the disease or its clinical symptoms, or(3) relieving the disease, i.e., causing regression of the disease orits clinical symptoms.

A “therapeutically-effective amount” means the amount of a compoundthat, when administered to a mammal for treating a disease, issufficient to effect such treatment for the disease. The“therapeutically-effective amount” will vary depending on the compound,the disease, and its severity and the age, weight, etc., of the mammalto be treated.

Pharmaceutical Formulations of the Compounds

In general, compounds will be administered in atherapeutically-effective amount by any of the accepted modes ofadministration for these compounds. The compounds can be administered bya variety of routes, including, but not limited to, oral, parenteral(e.g., subcutaneous, subdural, intravenous, intramuscular, intrathecal,intraperitoneal, intracerebral, intraarterial, or intralesional routesof administration), topical, intranasal, localized (e.g., surgicalapplication or surgical suppository), rectal, and pulmonary (e.g.,aerosols, inhalation, or powder). Accordingly, these compounds areeffective as both injectable and oral compositions. The compounds can beadministered continuously by infusion or by bolus injection.

The actual amount of the compound, i.e., the active ingredient, willdepend on a number of factors, such as the severity of the disease,i.e., the condition or disease to be treated, age, and relative healthof the subject, the potency of the compound used, the route and form ofadministration, and other factors.

Toxicity and therapeutic efficacy of such compounds can be determined bystandard pharmaceutical procedures in cell cultures or experimentalanimals, e.g., for determining the LD₅₀ (the dose lethal to 50% of thepopulation) and the ED₅₀ (the dose therapeutically effective in 50% ofthe population). The dose ratio between toxic and therapeutic effects isthe therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀.

The data obtained from the cell culture assays and animal studies can beused in formulating a range of dosage for use in humans. The dosage ofsuch compounds lies within a range of circulating concentrations thatinclude the ED₅₀ with little or no toxicity. The dosage may vary withinthis range depending upon the dosage form employed and the route ofadministration utilized. For any compound used, thetherapeutically-effective dose can be estimated initially from cellculture assays. A dose may be formulated in animal models to achieve acirculating plasma concentration range which includes the IC₅₀ (i.e.,the concentration of the test compound which achieves a half-maximalinhibition of symptoms) as determined in cell culture. Such informationcan be used to more accurately determine useful doses in humans. Levelsin plasma may be measured, for example, by high performance liquidchromatography.

The amount of the pharmaceutical composition administered to the patientwill vary depending upon what is being administered, the purpose of theadministration, such as prophylaxis or therapy, the state of thepatient, the manner of administration, and the like. In therapeuticapplications, compositions are administered to a patient alreadysuffering from a disease in an amount sufficient to cure or at leastpartially arrest the symptoms of the disease and its complications. Anamount adequate to accomplish this is defined as“therapeutically-effective dose.” Amounts effective for this use willdepend on the disease condition being treated as well as by the judgmentof the attending clinician depending upon factors such as the severityof the inflammation, the age, weight, and general condition of thepatient, and the like.

The compositions administered to a patient are in the form ofpharmaceutical compositions described supra. These compositions may besterilized by conventional sterilization techniques, or may be sterilefiltered. The resulting aqueous solutions may be packaged for use as is,or lyophilized, the lyophilized preparation being combined with asterile aqueous carrier prior to administration. It will be understoodthat use of certain of the foregoing excipients, carriers, orstabilizers will result in the formation of pharmaceutical salts.

The active compound is effective over a wide dosage range and isgenerally administered in a pharmaceutically- ortherapeutically-effective amount. The therapeutic dosage of thecompounds will vary according to, for example, the particular use forwhich the treatment is made, the manner of administration of thecompound, the health and condition of the patient, and the judgment ofthe prescribing physician. For example, for intravenous administration,the dose will typically be in the range of about 0.5 mg to about 100 mgper kilogram body weight. Effective doses can be extrapolated fromdose-response curves derived from in vitro or animal model test systems.Typically, the clinician will administer the compound until a dosage isreached that achieves the desired effect.

When employed as pharmaceuticals, the compounds are usually administeredin the form of pharmaceutical compositions. Pharmaceutical compositionscontain as the active ingredient one or more of the compounds above,associated with one or more pharmaceutically-acceptable carriers orexcipients. The excipient employed is typically one suitable foradministration to human subjects or other mammals. In making thecompositions, the active ingredient is usually mixed with an excipient,diluted by an excipient, or enclosed within a carrier which can be inthe form of a capsule, sachet, paper or other container. When theexcipient serves as a diluent, it can be a solid, semi-solid, or liquidmaterial, which acts as a vehicle, carrier, or medium for the activeingredient. Thus, the compositions can be in the form of tablets, pills,powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions,solutions, syrups, aerosols (as a solid or in a liquid medium),ointments containing, for example, up to 10% by weight of the activecompound, soft and hard gelatin capsules, suppositories, sterileinjectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the activecompound to provide the appropriate particle size prior to combiningwith the other ingredients. If the active compound is substantiallyinsoluble, it ordinarily is milled to a particle size of less than 200mesh. If the active compound is substantially water soluble, theparticle size is normally adjusted by milling to provide a substantiallyuniform distribution in the formulation, e.g., about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose,sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates,tragacanth, gelatin, calcium silicate, microcrystalline cellulose,polyvinylpyrrolidone, cellulose, sterile water, syrup, and methylcellulose. The formulations can additionally include: lubricating agentssuch as talc, magnesium stearate, and mineral oil; wetting agents;emulsifying and suspending agents; preserving agents such as methyl- andpropylhydroxy-benzoates; sweetening agents; and flavoring agents. Thecompositions of the invention can be formulated so as to provide quick,sustained, or delayed-release of the active ingredient afteradministration to the patient by employing procedures known in the art.

The quantity of active compound in the pharmaceutical composition andunit dosage form thereof may be varied or adjusted widely depending uponthe particular application, the manner or introduction, the potency ofthe particular compound, and the desired concentration. The term “unitdosage forms” refers to physically-discrete units suitable as unitarydosages for human subjects and other mammals, each unit containing apredetermined quantity of active material calculated to produce thedesired therapeutic effect, in association with a suitablepharmaceutical excipient.

The compound can be formulated for parenteral administration in asuitable inert carrier, such as a sterile physiological saline solution.The dose administered will be determined by route of administration.

Administration of therapeutic agents by intravenous formulation is wellknown in the pharmaceutical industry. An intravenous formulation shouldpossess certain qualities aside from being just a composition in whichthe therapeutic agent is soluble. For example, the formulation shouldpromote the overall stability of the active ingredient(s). Also, themanufacture of the formulation should be cost-effective. All of thesefactors ultimately determine the overall success and usefulness of anintravenous formulation.

Other accessory additives that may be included in pharmaceuticalformulations and compounds as follow: solvents: ethanol, glycerol,propylene glycol; stabilizers: EDTA (ethylene diamine tetraacetic acid),citric acid; antimicrobial preservatives: benzyl alcohol, methylparaben, propyl paraben; buffering agents: citric acid/sodium citrate,potassium hydrogen tartrate, sodium hydrogen tartrate, aceticacid/sodium acetate, maleic acid/sodium maleate, sodium hydrogenphthalate, phosphoric acid/potassium dihydrogen phosphate, phosphoricacid/disodium hydrogen phosphate; and tonicity modifiers: sodiumchloride, mannitol, dextrose.

The presence of a buffer is necessary to maintain the aqueous pH in therange of from about 4 to about 8. The buffer system is generally amixture of a weak acid and a soluble salt thereof, e.g., sodiumcitrate/citric acid; or the monocation or dication salt of a dibasicacid, e.g., potassium hydrogen tartrate; sodium hydrogen tartrate,phosphoric acid/potassium dihydrogen phosphate, and phosphoricacid/disodium hydrogen phosphate.

The amount of buffer system used is dependent on (1) the desired pH; and(2) the amount of drug. Generally, the amount of buffer used is able tomaintain a formulation pH in the range of 4 to 8. Generally, a 1:1 to10:1 mole ratio of buffer (where the moles of buffer are taken as thecombined moles of the buffer ingredients, e.g., sodium citrate andcitric acid) to drug is used.

A useful buffer is sodium citrate/citric acid in the range of 5 to 50 mgper ml. sodium citrate to 1 to 15 mg per ml. citric acid, sufficient tomaintain an aqueous pH of 4-6 of the composition.

The buffer agent may also be present to prevent the precipitation of thedrug through soluble metal complex formation with dissolved metal ions,e.g., Ca, Mg, Fe, Al, Ba, which may leach out of glass containers orrubber stoppers or be present in ordinary tap water. The agent may actas a competitive complexing agent with the drug and produce a solublemetal complex leading to the presence of undesirable particulates.

In addition, the presence of an agent, e.g., sodium chloride in anamount of about of 1-8 mg/ml, to adjust the tonicity to the same valueof human blood may be required to avoid the swelling or shrinkage oferythrocytes upon administration of the intravenous formulation leadingto undesirable side effects such as nausea or diarrhea and possibly toassociated blood disorders. In general, the tonicity of the formulationmatches that of human blood which is in the range of 282 to 288 mOsm/kg,and in general is 285 mOsm/kg, which is equivalent to the osmoticpressure corresponding to a 0.9% solution of sodium chloride.

An intravenous formulation can be administered by direct intravenousinjection, i.v. bolus, or can be administered by infusion by addition toan appropriate infusion solution such as 0.9% sodium chloride injectionor other compatible infusion solution.

The compositions are preferably formulated in a unit dosage form, eachdosage containing from about 5 to about 100 mg, more usually about 10 toabout 30 mg, of the active ingredient. The term “unit dosage forms”refers to physically discrete units suitable as unitary dosages forhuman subjects and other mammals, each unit containing a predeterminedquantity of active material calculated to produce the desiredtherapeutic effect, in association with a suitable pharmaceuticalexcipient.

The active compound is effective over a wide dosage range and isgenerally administered in a pharmaceutically effective amount. It willbe understood, however, that the amount of the compound actuallyadministered will be determined by a physician, in the light of therelevant circumstances, including the condition to be treated, thechosen route of administration, the actual compound administered, theage, weight, and response of the individual patient, the severity of thepatient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal activeingredient is mixed with a pharmaceutical excipient to form a solidpreformulation composition containing a homogeneous mixture of acompound of the present invention. When referring to thesepreformulation compositions as homogeneous, it is meant that the activeingredient is dispersed evenly throughout the composition so that thecomposition may be readily subdivided into equally effective unit dosageforms such as tablets, pills and capsules. This solid preformulation isthen subdivided into unit dosage forms of the type described abovecontaining from, for example, 0.1 to about 2000 mg of the activeingredient.

The tablets or pills may be coated or otherwise compounded to provide adosage form affording the advantage of prolonged action. For example,the tablet or pill can comprise an inner dosage and an outer dosagecomponent, the latter being in the form of an envelope over the former.The two components can be separated by an enteric layer which serves toresist disintegration in the stomach and permit the inner component topass intact into the duodenum or to be delayed in release. A variety ofmaterials can be used for such enteric layers or coatings, suchmaterials including a number of polymeric acids and mixtures ofpolymeric acids with such materials as shellac, cetyl alcohol, andcellulose acetate.

The liquid forms in which the novel compositions may be incorporated foradministration orally or by injection include aqueous solutions,suitably flavored syrups, aqueous or oil suspensions, and flavoredemulsions with edible oils such as cottonseed oil, sesame oil, coconutoil, or peanut oil, as well as elixirs and similar pharmaceuticalvehicles.

Compositions for inhalation or insufflation include solutions andsuspensions in pharmaceutically-acceptable, aqueous or organic solvents,or mixtures thereof, and powders. The liquid or solid compositions maycontain suitable pharmaceutically-acceptable excipients as describedsupra. Compositions in pharmaceutically-acceptable solvents may benebulized by use of inert gases. Nebulized solutions may be breatheddirectly from the nebulizing device or the nebulizing device may beattached to a face masks tent, or intermittent positive pressurebreathing machine. Solution, suspension, or powder compositions may beadministered from devices which deliver the formulation in anappropriate manner.

The compounds can be administered in a sustained release form. Suitableexamples of sustained-release preparations include semipermeablematrices of solid hydrophobic polymers containing the compounds, whichmatrices are in the form of shaped articles, e.g., films, ormicrocapsules. Examples of sustained-release matrices includepolyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) asdescribed by Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981)and Langer, Chem. Tech. 12: 98-105 (1982) or poly(vinyl alcohol)),polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acidand gamma ethyl-L-glutamate (Sidman et al., Biopolymers 22: 547-556,1983), non-degradable ethylene-vinyl acetate (Langer et al., supra),degradable lactic acid-glycolic acid copolymers such as the LUPRONDEPOT™ (i.e., injectable microspheres composed of lactic acid-glycolicacid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyricacid (EP 133,988).

The compounds can be administered in a sustained-release form, forexample a depot injection, implant preparation, or osmotic pump, whichcan be formulated in such a manner as to permit a sustained-release ofthe active ingredient. Implants for sustained-release formulations arewell-known in the art. Implants may be formulated as, including but notlimited to, microspheres, slabs, with biodegradable or non-biodegradablepolymers. For example, polymers of lactic acid and/or glycolic acid forman erodible polymer that is well-tolerated by the host.

Transdermal delivery devices (“patches”) may also be employed. Suchtransdermal patches may be used to provide continuous or discontinuousinfusion of the compounds in controlled amounts. The construction anduse of transdermal patches for the delivery of pharmaceutical agents iswell known in the art. See, e.g., U.S. Pat. No. 5,023,252, issued Jun.11, 1991, herein incorporated by reference. Such patches may beconstructed for continuous, pulsatile, or on-demand delivery ofpharmaceutical agents.

Direct or indirect placement techniques may be used when it is desirableor necessary to introduce the pharmaceutical composition to the brain.Direct techniques usually involve placement of a drug delivery catheterinto the host's ventricular system to bypass the blood-brain barrier.One such implantable delivery system used for the transport ofbiological factors to specific anatomical regions of the body isdescribed in U.S. Pat. No. 5,011,472, which is herein incorporated byreference.

Indirect techniques usually involve formulating the compositions toprovide for drug latentiation by the conversion of hydrophilic drugsinto lipid-soluble drugs. Latentiation is generally achieved throughblocking of the hydroxy, carbonyl, sulfate, and primary amine groupspresent on the drug to render the drug more lipid-soluble and amenableto transportation across the blood-brain barrier. Alternatively, thedelivery of hydrophilic drugs may be enhanced by intra-arterial infusionof hypertonic solutions which can transiently open the blood-brainbarrier.

In order to enhance serum half-life, the compounds may be encapsulated,introduced into the lumen of liposomes, prepared as a colloid, or otherconventional techniques may be employed which provide an extended serumhalf-life of the compounds. A variety of methods are available forpreparing liposomes, as described in, e.g., Szoka et al., U.S. Pat. Nos.4,235,871, 4,501,728 and 4,837,028 each of which is incorporated hereinby reference.

Pharmaceutical compositions are suitable for use in a variety of drugdelivery systems. Suitable formulations for use in the present inventionare found in Remington's Pharmaceutical Sciences, Mace PublishingCompany, Philadelphia, Pa., 17th ed. (1985).

In the examples below, if an abbreviation is not defined above, it hasits generally accepted meaning. Further, all temperatures are in degreesCelsius (unless otherwise indicated). The following Methods were used toprepare the compounds set forth below as indicated.

Example 1 Formulation 1

Hard gelatin capsules containing the following ingredients are prepared:

Quantity Ingredient (mg/capsule) Active Ingredient 30.0 Starch 305.0Magnesium stearate 5.0

The above ingredients are mixed and filled into hard gelatin capsules in340 mg quantities.

Example 2 Formulation 2

A tablet formula is prepared using the ingredients below:

Quantity Ingredient (mg/capsule) Active ingredient 25.0 Cellulose,microcrystalline 200.0 Colloidal silicon dioxide 10.0 Stearic acid 5.0

The components are blended and compressed to form tablets, each weighing240 mg.

Example 3 Formulation 3

A dry powder inhaler formulation is prepared containing the followingcomponents:

Ingredient Weight % Active Ingredient 5 Lactose 95

The active mixture is mixed with the lactose and the mixture is added toa dry powder inhaling appliance.

Example 4 Formulation 4

Tablets, each containing 30 mg of active ingredient, are prepared asfollows:

Quantity Ingredient (mg/capsule) Active Ingredient 30.0 mg Starch 45.0mg Microcrystalline cellulose 35.0 mg Polyvinylpyrrolidone 4.0 mg (as10% solution in water) Sodium Carboxymethyl starch 4.5 mg Magnesiumstearate 0.5 mg Talc 1.0 mg Total 120 mg

The active ingredient, starch, and cellulose are passed through a No. 20mesh U.S. sieve and mixed thoroughly. The solution ofpolyvinyl-pyrrolidone is mixed with the resultant powders, which arethen passed through a 16 mesh U.S. sieve. The granules so produced aredried at 50° to 60° C. and passed through a 16 mesh U.S. sieve. Thesodium carboxymethyl starch, magnesium stearate, and talc, previouslypassed through a No. 30 mesh U.S. sieve, are then added to the granules,which after mixing, are compressed on a tablet machine to yield tabletseach weighing 150 mg.

Example 5 Formulation 5

Capsules, each containing 40 mg of medicament, are made as follows:

Quantity Ingredient (mg/capsule) Active Ingredient 40.0 mg Starch 109.0mg Magnesium stearate 1.0 mg Total 150.0 mg

The active ingredient, cellulose, starch, an magnesium stearate areblended, passed through a No. 20 mesh U.S. sieve, and filled into hardgelatin capsules in 150 mg quantities.

Example 6 Formulation 6

Suppositories, each containing 25 mg of active ingredient, are made asfollows:

Ingredient Amount Active Ingredient 25 mg Saturated fatty acidsglycerides to 2,000 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve andsuspended in the saturated fatty acid glycerides previously melted usingthe minimum heat necessary. The mixture is then poured into asuppository mold of nominal 2.0 g capacity and allowed to cool.

Example 7 Formulation 7

Suspensions, each containing 50 mg of medicament per 5.0 ml dose, aremade as follows:

Ingredient Amount Active ingredient 50.0 mg Xanthan gum 4.0 mg Sodiumcarboxymethyl cellose (11%) 500 mg Microcrystalline cellulose (89%)Sucrose 1.75 g Sodium benzoate 10.0 mg Flavor and color q.v. Purifiedwater to 5.0 ml

The medicament, sucrose, and xanthan gum are blended, passed through aNO. 10 mesh U.S. sieve, and then mixed with a previously made solutionof the microcrystalline cellulose and sodium carboxymethyl cellulose inwater. The sodium benzoate, flavor, and color are diluted with some ofthe water and added with stirring. Sufficient water is then added toproduce the required volume.

Example 8 Formulation 8

Hard gelatin tablets, each containing 15 mg of active ingredient, aremade as follows:

Quantity Ingredient (mg/capsule) Active Ingredient 15.0 mg Starch 407.0mg Magnesium stearate 3.0 mg Total 425.0 mg

The active ingredient, cellulose, starch, and magnesium stearate areblended, passed through a No. 20 mesh U.S. sieve, and filled into hardgelatin capsules in 560 mg quantities.

Example 9 Formulation 9

An intravenous formulation may be prepared as follows:

Ingredient (mg/capsule) Active Ingredient 250.0 mg Isotonic saline 1000ml

Therapeutic compound compositions generally are placed into a containerhaving a sterile access port, for example, an intravenous solution bagor vial having a stopper pierceable by a hypodermic injection needle orsimilar sharp instrument.

Example 10 Formulation 10

A topical formulation may be prepared as follows:

Ingredient Quantity Active Ingredient 1-10 g Emulsifying Wax 30 g LiquidParaffin 20 g White Soft Paraffin to 100 g

The white soft paraffin is heated until molten. The liquid paraffin andemulsifying wax are incorporated and stirred until dissolved. The activeingredient is added and stirring is continued until dispersed. Themixture is then cooled until solid.

Example 11 Formulation 11

An aerosol formulation may be prepared as follows: A solution of thecandidate compound in 0.5% sodium bicarbonate/saline (w/v) at aconcentration of 30.0 mg/mL is prepared using the following procedure:

Preparation of 0.5% Sodium Bicarbonate/Saline Stock Solution: 100.0 mL

Ingredient Gram/100.0 mL Final Concentration Sodium Bicarbonate 0.5 g0.5% Saline q.s. ad 100.0 mL q.s. ad 100%

Procedure:

1. Add 0.5 g sodium bicarbonate into a 100 mL volumetric flask.2. Add approximately 90.0 mL saline and sonicate until dissolved.3. Q.S. to 100.0 mL with saline and mix thoroughly.

Preparation of 30.0 mg/mL Candidate Compound: 10.0 mL

Ingredient Gram/100.0 mL Final Concentration Candidate Compound 0.300 g30.0 mg/mL .05% Sodium q.s. ad 10.0 mL q.s. ad 100% Bicarbonate/SalineStock Solution

Procedure:

1. Add 0.300 g of the candidate compound into a 10.0 mL volumetricflask.2. Add approximately 9.7 mL of 0.5% sodium bicarbonate/saline stocksolution.3. Sonicate until the candidate compound is completely dissolved.4. Q.S. to 10.0 mL with 0.5% sodium bicarbonate/saline stock solutionand mix.

Example 12 Synthesis of4-tert-butyl-N-[[2-chloro-4-(methylamino)phenyl]-carbamothioyl]benzamidehydrochloride (Compound 5)

4-tert-butyl-N-[[2-chloro-4-(methylamino)phenyl]-carbamothioyl]benzamidehydrochloride (Compound 5) was synthesized according to the followingscheme:

Synthesis of 4-tert-butylbenzoyl isothiocyanate (Intermediate A)

To a stirred solution of 4-tert-butylbenzoyl chloride (6 g, 198 mmol) inacetone (250 mL) was added ammonium thiocynate (28 g, 237 mmol). Theresulting yellow suspension was stirred at room temperature for 2 hours,condensed to dryness and then reconstituted through the addition ofethyl acetate (200 mL). The organic portion was washed with a saturatedsodium bicarbonate solution (2×200 ml) and brine (200 mL). The resultingorganic phase was dried over anhydrous sodium sulfate and concentratedto a sticky liquid. The residue was chilled in a −10° C. freezer to give37 grams of Intermediate A as a yellow solid (88%).

Synthesis of4-tert-butyl-N-[(2-chloro-4-nitro-phenyl)carbamothioyl]benzamide(compound 5-1)

To a stirred solution of intermediate A (5.85 g, 24.6 mmol) in acetone(120 mL) was added 2-chloro-4-nitroanaline (4.25 g, 24.6 mmol) in oneportion. The resulting yellow solution was stirred at room temperaturefor 36 hours, condensed and purified via normal phase columnchromatography using a solvent system of 0-10% ethyl acetate in hexanesto yield 8.6 g of compound 5-1 as a yellow solid (89%).

Synthesis ofN-[(4-amino-2-chloro-phenyl)carbamothioyl]-4-tert-butyl-benzamide(compound 5-2)

To a stirred solution of compound 5-1 (8.6 g, 22 mmol) in acetonitrile(200 mL) was added ammonium chloride (17.6 g, 330 mmol) and water (100mL). To the resulting light yellow suspension was added iron powder(18.5 g, 330 mmol) which resulted in a dark green mixture. Afterstirring for 24 hours, the reaction was filtered through a pad of Celiteand the filter cake was washed with ethyl acetate. The organic portionof the filtrate was removed and the aqueous portion was extracted twicewith ethyl acetate. The combined organic portions were washed with brineand dried over anhydrous sodium sulfate. The resulting solution wasconcentrated to dryness to yield 6.6 g of compound 5-2 as a yellow solid(83%).

Synthesis of4-tert-butyl-N-[[2-chloro-4-(methylamino)phenyl]carbamothioyl]benzamide(compound 5-3)

To a stirred solution of compound 5-2 (1.60 g, 4.4 mmol) intetrahydrofuran (100 mL) was added formaldehyde (37% aqueous, 0.4 mL,4.8 mmol), sodium triacetoxyborohydride (0.6 mL, 17.6 mmol) and aceticacid (0.5 mL, 8.8 mmol). The resulting yellow suspension was stirred atroom temperature for 36 hours. The reaction mixture was diluted withdichloromethane (200 mL) and washed with a saturated sodium bicarbonatesolution and brine. The organic layer was concentrated and then purifiedvia normal phase column chromatography using 0-5% ethyl acetate indichloromethane to yield 530 mg of compound 5-3 as a yellow solid (32%).

Synthesis of4-tert-butyl-N-[[2-chloro-4-(methylamino)phenyl]carbamothioyl]benzamidehydrochloride (compound 5)

To an ice-water bath cooled solution of 5-3 (200 mg, 0.53 mmol) indichloromethane (6 mL) was added 2M HCl in diethyl ether (0.35 mL, 0.69mmol). The resulting red solution was stirred at room temperature for 30minutes. After removing solvents, the material was dried under highvacuum to yield 210 mg of compound 5 as a yellow solid (96%).

Example 13 Synthesis of4-tert-butyl-N-[[4-[(2-chlorophenyl)-methylamino]-3-methoxy-phenyl]-carbamothioyl]-benzamide(Compound 3)

4-tert-butyl-N-[[4-[(2-chlorophenyl)-methylamino]-3-methoxy-phenyl]-carbamothioyl]-benzamide(compound 3) was synthesized according to the following scheme:

Synthesis of tert-butylN-[4-[(4-tert-butylbenzoyl)carbamothioylamino]-2-methoxy-phenyl]carbamate(compound 3-1)

To a solution of intermediate A (see Example 12; 1.8 g, 8.22 mmol) inacetone (30 mL) was added (4-Amino-2-methoxy-phenyl)-carbamic acidtert-butyl ester (1.95 g, 8.22 mmol). The reaction mixture was stirredat room temperature for 16 hours, concentrated to dryness and treatedwith ethyl acetate (200 mL). The organic portion was washed with waterand a brine solution followed by evaporation of solvent. The residue waspurified by normal phase column chromatography utilizing 10-50% ethylacetate in hexanes to provide 2.41 g of compound 3-1 as a pale whitesolid (64%).

Synthesis ofN-[(4-amino-3-methoxy-phenyl)carbamothioyl]-4-tert-butyl-benzamidehydrochloride (compound 3-2)

A solution of compound 3-1 (12 g, 26.2 mmol) in anhydrousdichloromethane (180 mL) was cooled to 0° C. To the reaction mixture wasadded a solution of trifluoroacetic acid (20 mL, 262 mmol) indichloromethane (70 mL). After stirring at room temperature for 16hours, the solvent was removed and the residue was co-evaporated withanhydrous acetonitrile. The remaining oil was treated with diethyl etherfollowed by the addition of 2.0M HCl in diethyl ether (15 mL). Thesolution was stirred at room temperature for 2 hours and thenconcentrated to provide a white solid. The solid was washed with copiousamounts of diethyl ether to afford 9.2 g of compound 3-2 as a whitesolid (89%).

Synthesis of4-tert-butyl-N-[[4-[(2-chlorophenyl)methylamino]-3-methoxy-phenyl]carbamothioyl]benzamide(compound 3)

To a solution of compound 3-2 (150 mg, 0.381 mmol) in dichloromethane (4mL) was added 2-chlorobenzaldehyde (54 mg, 0.572 mmol). The solution wasstirred at room temperature for 1 hour followed by the addition oftriacetoxyborohydride (121 mg, 0.572 mmol). After stirring thesuspension for 18 hours at room temperature, the reaction was quenchedby the addition of a saturated sodium bicarbonate solution (3 mL) andconcentrated. The residue was treated with ethyl acetate, washed withbrine and dried over anhydrous sodium sulfate. After removing solvents,the residue was purified by normal phase column chromatography eluting15-45% ethyl acetate in hexanes to yield 35 mg of compound 3 as a yellowsolid (19%).

Example 14 Synthesis ofN-[2-amino-4-[(4-tert-butylbenzoyl)-carbamothioylamino]-phenyl]-2-chloro-benzamidehydrochloride (compound 6)

N-[2-amino-4-[(4-tert-butylbenzoyl)-carbamothioylamino]-phenyl]-2-chloro-benzamidehydrochloride was synthesized according to the following scheme:

Synthesis of tert-butyl N-(2-benzamido-5-nitro-phenyl)carbamate(compound 6-1)

To a solution of 2-chlorobenzoyl chloride (100 μL, 0.789 mmol) anddiisopropylethylamine (165 μL, 0.947 mmol) in tetrahydrofuran (8 mL) at0° C. was added 4-nitrobenzene-1,2-diamine (200 mg, 0.789 mmol) dropwise. The reaction was allowed to warm to room temperature and stir for3 hours. The reaction mixture was concentrated and the resulting residuewas purified by normal phase column chromatography utilizing 75% hexanesin ethyl acetate to produce 452 mg of compound 6-1 as a solid aftervacuum drying (>99%).

Synthesis of tert-butyl N-(5-amino-2-benzamido-phenyl)carbamate(compound 6-2)

To a solution of compound 6-1 (0.452 g, 0.789 mmol) in tetrahydrofuan (5mL) was added a saturated ammonium chloride solution (3 mL) followed byiron powder (220 mg, 3.95 mmol). The reaction was stirred for 72 hoursand then filtered through Celite. The filtrate was concentrated and theresulting residue was purified by normal phase column chromatographyusing 0.5-1% methanol in, dichloromethane to produce 152 mg of compound6-2 as a solid (53%).

Synthesis of tert-butylN-[5-[(4-tert-butylbenzoyl)carbamothioylamino]-2-[(2-chlorobenzoyl)amino]phenyl]-carbamate(compound 6-3)

To a solution of compound 6-2 (99.7 mg, 0.42 mmol) in acetone (8 mL) wasadded intermediate A (see Example 12; 152 mg, 0.42 mmol). The reactionwas stirred for 2 hours at room temperature and then concentrated. Theresulting residue was purified by normal phase column chromatographyeluting 75% hexanes in ethyl acetate to produce 238 mg of compound 6-3as a solid (97%).

Synthesis ofN-[2-amino-4-[(4-tert-butylbenzoyl)carbamothioylamino]phenyl]-2-chloro-benzamidehydrochloride (6)

To a solution of compound 6-3 (237 mg, 0.40 mmol) in dichloromethane (2mL) at 0° C. under argon was added a 50% solution of trifluoroaceticacid in dichloromethane (8 mL). The reaction was stirred for 3 hours atroom temperature and then concentrated. The residue was dissolved indimethylformamide and purified by prep-HPLC to afford 148 mg of a solidfollowing vacuum drying. A solution of 79 mg of the free base wasdissolved in dichloromethane (2 mL) and cooled with an ice-water bathfollowed by the slow addition of 2.0M HCl in diethyl ether (2 mL). Themixture was evaporated immediately to afford 74 mg of compound 6 as abrown solid (88%).

Example 15 Synthesis of4-tert-butyl-N-[(2-chloro-5-methyl-anilino)-ethylsulfanyl-methylene]benzamide(compound 9)

4-tert-butyl-N-[(2-chloro-5-methyl-anilino)-ethylsulfanyl-methylene]benzamidewas synthesized according to the following scheme:

Synthesis of4-tert-butyl-N-[(2-chloro-5-methyl-phenyl)carbamothioyl]benzamide(compound 9-1)

To a solution of 2-chloro-5-methylphenylamine (72.8 mg, 0.514 mmol) inacetone (3 mL) was added a solution of intermediate A (see Example 12;122 mg, 0.556 mmol) in acetone (3 mL). The reaction was stirred at roomtemperature for 2 hours and then concentrated. The resulting residue waspurified by normal phase column chromatography eluting 85% hexanes inethyl acetate to yield 187 mg of compound 9-1 as a solid followingvacuum drying (>99%).

Synthesis of4-tert-butyl-N-[(2-chloro-5-methyl-anilino)-ethylsulfanylmethylene]benzamide(compound 9)

To a solution of compound 9-1 (150 mg, 0.42 mmol) in dimethylformamide(4 mL) was added potassium carbonate (72 mg, 0.52 mmol) followed byiodoethane (65 mg, 0.42 mmol). The reaction mixture was stirred at roomtemperature for 4 hours. After the reaction period, the mixture wasdiluted with ethyl acetate (50 mL), washed with brine (2×15 mL) andwater (15 mL), dried over anhydrous sodium sulfate and concentratedunder reduced pressure. The crude material was purified by normal phasecolumn chromatography using a gradient elution of 100 to 98% hexanes inethyl acetate to produce 60 mg of compound 9 as a white powder (36%).

Example 16 Summary of the Biological Assays Used Assay Development

Sensitive and reproducible high throughput screening (HTS) assays wereestablished to measure cytopathic effect induced by infection witheither Rift Valley fever virus (RVFV) or La Crosse virus (LACV), virusesthat represent two distinct genera in the genetically diverseBunyaviridae family. To determine the amount of LACV stock required toproduce complete CPE, Vero cell monolayers were seeded on 96-well platesand infected with 2-fold serial dilutions of the LACV stock. At 3, 4, or5 days post-infection, replicate cultures were fixed with 5%glutaraldehyde and stained with 0.1% crystal violet. Virus-inducedcytopathic effect (CPE) was quantified spectrophotometrically at OD570.From this analysis, a 1:20,000 dilution of LACV stock (MOI of 0.01pfu/cell) was chosen for use in the HTS assay, and the optimum time ofinfection at this dilution prior to fixation and crystal violet stainingwas determined to be 4 days. A CPE assay used to measure CPE caused bythe RVFV vaccine strain MP-12 (provided by ViroPharma, Inc.) wassimilarly optimized using Vero cells and a 1:12,000 dilution of RVFVstock (0.03 PFU/cell).

Virus Stocks

RVFV vaccine strain MP12 and LACV were provided by ViroPharma, Inc.Virus stocks were prepared in BHK-21 cells infected at low multiplicity(0.01 plaque forming units (PFU)/cell) and harvested when at the time ofmaximum CPE. The samples were frozen and thawed to releasecell-associated virus. The cell debris was removed by low-speedcentrifugation, and the resulting virus suspension was stored in 1 mlaliquots at −80° C. The titer of the virus suspension was quantified bystandard assay on Vero cells.

Primary HTS Screening

The LACV and RVFV CPE assays were used to identify antiviral compoundsfrom the SIGA chemical library capable of inhibiting both LACV-inducedand RVFV-induced CPE. Each evaluation run consisted of 48×96-well plateswith 80 compounds per plate to generate 3,840 data points per run pervirus, and each run incorporated ribavirin controls (EC₅₀ value 0.75 mMfor LACV and 0.3 mM for RVFV). Compounds were dissolved in DMSO anddiluted in medium such that the final concentration in each well was 5μM compound and 0.5% DMSO. The compounds were added robotically to theculture medium using the PerkinElmer MultiPROBE® II HT PLUS roboticsystem. Following compound addition, cultures were infected with LACV orRVFV as above. After 4 days incubation, plates were processed and theCPE quantified on a PerkinElmer EnVision II plate reader system.

The results of these experiments indicated that the 96-well assay formatis robust and reproducible. The S/B ratio (ratio of signal of cellcontrol wells (signal) to virus control wells (background)) has averaged9.0±1.8. The well-to-well variability was determined for each individualplate and found to have a coefficient of variance of less than 15% forboth positive control and negative control wells, and overallassay-to-assay variability was less than 15%. Taken together, theseresults show that a sensitive and reproducible HTS assay has beensuccessfully developed to evaluate our compound library for inhibitorsof LACV and RVFV replication.

Virus Yield Assay

Vero cells were seeded onto 24-well plates in complete media andinclubated overnight at 37° C. The following day, compounds were addedto triplicate wells of the plate across a range of concentrationsbetween 25 μM and 0.1 nM. Control wells lacking virus or containing DMSOvehicle only were also prepared in triplicate. Wells were then infectedwith Tacaribe virus at an MOI of 0.01 and incubated for 72 hours at 37°C. Supernantants harvested at 72 hours from each well were seriallydiluted (10⁻¹ to 10⁻⁵) and each dilution was plated onto a freshmonolayer of Vero cells in duplicate, and overlayed with 3 ml of 1.1%SeaPlaque agarose in media (MEM+5% FBS+P/S). Cells were incubated for 7days at 37° C. Following incubation, cells were fixed with 5%gluteraldehyde and stained with 0.1% crystal violet. Viral plaquescounted were used to calculate yield reduction as compared to cellstreated with DMSO vehicle.

Inhibitory Potency

Chemically tractable hits identified in either the LACV or the RVFVprimary screens were subsequently tested for potency against both LACVand RVFV in cell culture. This secondary screen serves to confirm theresult from the primary assay, determine the effective dose range of thecompound, and identify any compounds from the individual primary screensthat have broad spectrum activity against both RVFV and LACV. Doseresponse curves are generated by measuring virus replication in thepresence of a range of compound concentrations. Typically, eightcompound concentrations are used (25, 8, 2.56, 0.81, 0.26, 0.084, 0.027and 0.009 μM) in order to generate inhibition curves suitable forcalculating EC₅₀ values. Compounds that have EC₅₀ values<25 μM againstboth LACV and RVFV were further evaluated for selectivity.

Inhibitory Selectivity

To determine if compounds are selective for inhibition of virusreplication and not simply toxic to cells, cytotoxicity of each hit thatproduces EC₅₀ values<10 μM is determined by an Alamar Blue fluorometricmethod, which measures the in situ reduction of resazurin(7-hydroxy-3H-phenoxazin-3-one 10-oxide) by mitochondrial enzymes inmetabolically active cells. The Alamar Blue assay is used to generatedose response curves and the cytotoxic concentration that kills 50% ofcells (CC₅₀) is determined. Cells are seeded at subconfluent densitiesin order to identify compounds that may be cytostatic.

Spectrum of Activity

Hits that were potent and selective against both RVFV and LACV weretested in additional ongoing antiviral HTS programs at SIGA against aspectrum of pathogens from different viral and bacterial families.Testing for in vitro antiviral activity was performed using clinicallyrelevant members of multiple virus families including vaccinia virus andmonkeypox virus (Poxviridae), tacaribe virus and lymphocyticchoriomeningitis virus (Arenaviridae), encephalomyocarditis virus(Picornaviridae), Sindbis virus (Togaviridae), dengue fever virus(Flaviviridae), Ebola virus (Filoviridae), Andes virus (Bunyaviridae),respiratory syncytial virus (Paramyxoviridae), influenza virus(Orthomyxoviridae) human immunodeficiency virus (Retroviridae). CPEassays for vaccinia virus, Sindbis virus and encephalomyocarditis viruswere carried out in a manner similar to that described for LACV andRVFV. Antiviral activities against Ebola virus, human immunodeficiencyvirus, lymphocytic choriomeningitis virus, and dengue virus wereassessed using virus yield assays similar to that described for tacaribevirus. MIC values for compounds 1, 2, and 3 against Chlamydophila caviaewere determined using a fluorescent marker to label intracellularbacterial growth in cell culture. Briefly, compounds were delivered inmedia to Vero cells across a range of concentrations (25, 8, 2.56, 0.81,0.26, 0.084, 0.027 and 0.0075 μM). Cells were then inoculated with C.caviae at a multiplicity of infection of 0.8. Infected cells werecentrifuged for 40 min (1200 rpm, 37° C.) and then incubated in astandard cell culture incubator for 20 hours. At this point media wereremoved from each well and a fluorescent tracker of host Golgimetabolism (NBD C6-ceramide, Molecular Probes cat # N1154: 1 μg/ml inPBS) was added to the cells. NBD-C6-ceramide traffics to intracellularChlamydia within infected cells and the abundance of label can bemeasured using fluorescein or GFP channels on a fluorimeter orfluorescent microscope. The label was incubated on cells for 30 min inthe cell culture incubator and then replaced with MEM-10. After 3 hr inthe incubator, medium was removed and replaced with PBS. The developmentof Chlamydia in cells was quantified by fluorescent measurement ofretained label, and by visual evaluation of the infected cells. Forinfluenza virus EC50 determination, A549 cells were plated in flatbottom, 96-well plates. Compounds were delivered in media to A549 cellsacross a range of concentrations (25, 8, 2.56, 0.81, 0.26, 0.084, 0.027and 0.0075 μM). Cells were then inoculated with influenza virus in mediacontaining 4 μg/ml TPCK-treated trypsin and incubated at 37 C for 72hours. Following incubation, 25 ul of supernatant from infected wellswas transferred to a separate, white, 96-well assay plate. 75 μl ofMUNANA neuraminidase substrate (20 mM in EMEM-0) was added to each well.Plates were incubated at 37 C for 1 hour and 100 μl of stop solution wasadded to each well. Plates were read at excitation wavelength of 360 nMand emission wavelength of 465 nM.

Example 17 Determining Anti-Viral and Anti-Bacterial Activity ofCompounds of the Invention

The spectrum of activity of various compounds of the present inventionagainst a broad range of viral and intracellular bacterial targets wasmeasured as indicated above and is shown in Tables 9-15 below.

TABLE 9 Anti-Viral and Anti-Bacterial Activity of certain novelcompounds of Formula I of the present invention. Avg Activity (LACV) AvgActivity (C. Caviae) Misc Activity Avg Activity (VV) A: EC50 ≦ 1 μM; A:EC50 ≦ 1 μM; A: EC50 ≦ 1 μM; A: EC50 ≦ 1 μM; B: 1 < EC50 ≦ 10 μM; B: 1 <EC50 ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; C: 10 < EC50 ≦25 μM; C: 10 < EC50 ≦ 25 μM; C: 10 < EC50 ≦ 25 μM; C: 10 < EC50 ≦ 25 μM;D: >25 μM D: >25 μM; D: >25 μM; Compound D: >25 μM n.d.: not determinedn.d.: not determined n.d.: not determined 1 A A A Influenza: A 4 A A An.d. 5 A A A n.d. 11 A B A Dengue: A Influenza: B Ebola: n.d. MPX: n.d.13 B A A n.d. 15 B A A n.d. 18 B B A Dengue: A Tacaribe: A Ebola: n.d.MPX: n.d. 19 B B A n.d. 21 B B A Dengue: A Tacaribe: A Influenza: AEbola: n.d. MPX: n.d. 22 B B A n.d. 29 B D n.d. n.d. 36 C D A n.d.

TABLE 10 Anti-Viral and Anti-Bacterial Activity of certain compounds ofFormula I of the present invention. Avg Activity (C. Caviae) Misc VirusActivity Avg Activity (VV) Avg Activity (LACV) A: EC50 ≦ 1 μM; A: EC50 ≦1 μM; A: EC₅₀ ≦ 1 μM; A: EC50 ≦ 1 μM; B: 1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦10 μM; B: 1 < EC₅₀ ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; C: 10 < EC50 ≦ 25 μM;C: 10 < EC50 ≦ 25 μM; C: 10 < EC₅₀ ≦ 25 μM; C: 10 < EC50 ≦ 25 μM; D: >25μM; D: >25 μM; Compound D: >25 μM D: >25 μM n.d.: not determined n.d.:not determined 40 A A A Dengue: A Tacaribe: A Influenza: A Ebola: C MPX:n.d. Rift Valley Fever: A Lymphocytic Choriomeningitis: A (reduces yield>10⁴-fold) 42 A A A n.d. 44 A A A n.d. 45 A B A Dengue: A Tacaribe: AInfluenza: A Ebola: n.d. MPX: n.d. 47 B A A n.d. 48 B A A Dengue: ATacaribe: A Influenza: B Ebola: n.d. MPX: n.d. 49 B A B Data for HClsalt Dengue: A Tacaribe: A Influenza: A Ebola: n.d. MPX: n.d. 50 B B An.d. 51 B B A n.d. 52 B B A n.d. 53 B B A n.d. 54 B B A n.d. 55 B B An.d. 56 B B A n.d. 57 B B A n.d. 58 B B A n.d. 59 B B A n.d. 60 B B An.d. 61 B B B n.d. 62 B B B n.d. 63 B B B n.d. 65 B B B n.d. 66 B D An.d. 67 B D A n.d. 70 B n.d. n.d. n.d. 71 C D A n.d.

TABLE 11 Anti-Viral and Anti-Bacterial Activity of certain novelcompounds of Formula II of the present invention. Avg Activity (LACV)Avg Activity (C. Caviae) Misc Activity Avg Activity (VV) A: EC50 ≦ 1 μM;A: EC50 ≦ 1 μM; A: EC50 ≦ 1 μM; A: EC50 ≦ 1 μM; B: 1 < EC50 ≦ 10 μM; B:1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; C: 10 < EC50≦ 25 μM; C: 10 < EC50 ≦ 25 μM; C: 10 < EC50 ≦ 25 μM; C: 10 < EC50 ≦ 25μM; D: >25 μM D: >25 μM; D: >25 μM; Compound D: >25 μM n.d.: notdetermined n.d.: not determined n.d.: not determined 2 A A A n.d. 3 A AA n.d. 6 A A A Dengue: A Tacaribe: A Influenza: A Ebola: B MPX: n.d. 7 AA A n.d. 8 A A A n.d. 12 A D A n.d. 23 B B A n.d. 24 B B A n.d. 27 B D An.d. 28 B D A n.d. 30 B n.d. A n.d. 31 B n.d. A n.d. 32 C C A n.d. 34 CD B n.d.

TABLE 12 Anti-Viral and Anti-Bacterial Activity of certain compounds ofFormula II of the present invention. Avg Activity (C. Caviae) Misc VirusActivity Avg Activity (VV) Avg Activity (LACV) A: EC50 ≦ 1 μM; A: EC50 ≦1 μM; A: EC₅₀ ≦ 1 μM; A: EC50 ≦ 1 μM; B: 1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦10 μM; B: 1 < EC₅₀ ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; C: 10 < EC50 ≦ 25 μM;C: 10 < EC50 ≦ 25 μM; C: 10 < EC₅₀ ≦ 25 μM; C: 10 < EC50 ≦ 25 μM; D: >25μM; D: >25 μM; Compound D: >25 μM; D: >25 μM; n.d.: not determined n.d.:not determined 39 A A A Dengue: A Tacaribe: A Influenza: A Ebola: A MPX:n.d. Rift Valley Fever: A Andes: A (reduces yield >100-fold) Sindbis: AEncephalomyocarditis: A Respiratory Syncytial: A LymphocyticChoriomeningitis: A (reduces yield >10⁴-fold) HIV-1: A 43 A A A n.d.

TABLE 13 Anti-Viral and Anti-Bacterial Activity of certain novelcompounds of Formula III of the present invention. Avg Activity (LACV)Avg Activity (C. Caviae) Misc Activity Avg Activity (VV) A: EC50 ≦ 1 μM;A: EC50 ≦ 1 μM; A: EC50 ≦ 1 μM; A: EC50 ≦ 1 μM; B: 1 < EC50 ≦ 10 μM; B:1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; C: 10 < EC50≦ 25 μM; C: 10 < EC50 ≦ 25 μM; C: 10 < EC50 ≦ 25 μM; C: 10 < EC50 ≦ 25μM; D: >25 μM; D: >25 μM; D: >25 μM; Compound D: >25 μM; n.d.: notdetermined n.d.: not determined n.d.: not determined 9 A A A n.d. 10 A AB n.d. 14 B A A n.d.

TABLE 14 Anti-Viral and Anti-Bacterial Activity of certain novelcompounds of the present invention. Avg Activity (LACV) Avg Activity (C.Caviae) Misc Activity Avg Activity (VV) A: EC50 ≦ 1 μM; A: EC50 ≦ 1 μM;A: EC50 ≦ 1 μM; A: EC50 ≦ 1 μM; B: 1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦ 10μM; B: 1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; C: 10 < EC50 ≦ 25 μM; C:10 < EC50 ≦ 25 μM; C: 10 < EC50 ≦ 25 μM; C: 10 < EC50 ≦ 25 μM; D: >25μM; D: >25 μM; D: >25 μM; Compound D: >25 μM; n.d.: not determined n.d.:not determined n.d.: not determined 16 B B A n.d. 17 B B A Dengue: ATacaribe: A Influenza: A Ebola: n.d. MPX: n.d. 20 B B A Dengue: ATacaribe: A Influenza: A Ebola: n.d. MPX: n.d. 25 B D B n.d. 26 B D Cn.d. 33 C D D n.d. 35 C D B n.d. 37 D B n.d. n.d. 38 D B D n.d.

TABLE 15 Anti-Viral and Anti-Bacterial Activity of certain compounds ofthe present invention. Avg Activity (C. Caviae) Misc Virus Activity AvgActivity (VV) Avg Activity (LACV) A: EC50 ≦ 1 μM; A: EC50 ≦ 1 μM; A:EC₅₀ ≦ 1 μM; A: EC50 ≦ 1 μM; B: 1 < EC50 ≦ 10 μM; B: 1 < EC50 ≦ 10 μM;B: 1 < EC₅₀ ≦ 10 μM; B: 1 < EC50 ≦ 10 μM; C: 10 < EC50 ≦ 25 μM; C: 10 <EC50 ≦ 25 μM; C: 10 < EC₅₀ ≦ 25 μM; C: 10 < EC50 ≦ 25 μM; D: >25 μM;D: >25 μM; Compound D: >25 μM; D: >25 μM; n.d.: not determined n.d.: notdetermined 41 A A A n.d. 46 A B A n.d. 64 B B B n.d. 68 B D B n.d. 69 BD D n.d. 72 C D C n.d. 73 C D D n.d. 74 D B D n.d.

The invention has been described in terms of preferred embodimentsthereof, but is more broadly applicable as will be understood by thoseskilled in the art. The scope of the invention is only limited by thefollowing claims.

1-175. (canceled)
 176. A method for the treatment of a viral orbacterial infection or disease associated therewith wherein the viralinfection is caused by a virus family selected from the group consistingof: Bunyaviridae, Poxviridae, Arenaviridae, Picornaviridae, Togaviridae,Flaviviridae, Filoviridae, Paramyxoviridae, Orthomyxoviridae andRetroviridae, comprising administering in a therapeutically effectiveamount to a mammal in need thereof, a compound of Formula II below or apharmaceutically acceptable salt thereof:

wherein X is selected from the group consisting of oxygen and NH; Y isselected from the group consisting of: —CH₂—, —C(═O)—, —C(═S)— and—C(═NH)—; A is selected from the group consisting of: N and CR⁵; B isselected from the group consisting of: N and CR⁶; R¹ is selected fromthe group consisting of: hydrogen and ethyl; R² is selected from thegroup consisting of: hydrogen and chloro; R³ is selected from the groupconsisting of: hydrogen, methoxy, amino and hydroxyl; R⁴ is selectedfrom the group consisting of: hydrogen, chloro and amino; R⁵ is selectedfrom the group consisting of hydrogen and aminomethyl; and R⁶ isselected from the group consisting of hydrogen, amino and aminomethyl.177. The method of claim 176, wherein X is oxygen.
 178. The method ofclaim 176, wherein Y is —CH₂—.
 179. The method of claim 176, wherein Yis —C(═O)—.
 180. The method of claim 176, wherein A is C—H.
 181. Themethod of claim 176, wherein B is C—H.
 182. The method of claim 176,wherein R¹ is hydrogen.
 183. The method of claim 176, wherein R² ishydrogen.
 184. The method of claim 176, wherein R³ is methoxy.
 185. Themethod of claim 176, wherein R⁴ is chloro.
 186. The method of claim 176,wherein each of R⁵ and R⁶ is hydrogen.
 187. The method of claim 176,wherein the compound of Formula II is selected from the group consistingof:N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-hydroxy-phenyl]-2-chloro-benzamide;4-tert-butyl-N-[[4-[(2-chlorophenyl)-methylamino]-3-methoxy-phenyl]-carbamothioyl]-benzamide;N-[2-amino-4-[(4-tert-butylbenzoyl)-carbamothioylamino]-phenyl]-2-chloro-benzamidehydrochloride;N-[(4-benzamido-2-chloro-phenyl)carbamothioyl]-4-tert-butyl-benzamide;4-tert-butyl-N-[[4-[(2-chlorobenzene-carbothioyl)amino]-3-methoxy-phenyl]-carbamothioyl]benzamide;4-(aminomethyl)-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamidehydrochloride;N-[4-[(4-tert-butylbenzene-carboximidoyl)-carbamothioylamino]-2-methoxy-phenyl]-2-chloro-benzamide;4-tert-butyl-N-[[4-[(2-chlorobenzene-carboximidoyl)amino]-3-methoxy-phenyl]-carbamothioyl]benzamide;3-(aminomethyl)-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamidehydrochloride;2-amino-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamide;N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]pyridine-3-carboxamide;N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]pyridine-4-carboxamide;N-[[4-[(4-aminobenzoyl)amino]-3-methoxy-phenyl]-carbamothioyl]-4-tert-butyl-benzamidehydrochloride;N-[4-[(4-tert-butylbenzoyl)-carbamothioyl-ethyl-amino]-2-methoxy-phenyl]-2-chloro-benzamide;N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]-2-chloro-benzamide;and N-[(4-benzamidophenyl)-carbamothioyl]-4-tert-butyl-benzamide. 188.The method of claim 187, wherein the compound of Formula II isN-[2-amino-4-[(4-tert-butylbenzoyl)-carbamothioylamino]-phenyl]-2-chloro-benzamidehydrochloride.
 189. The method of claim 176, wherein the mammal is ahuman.
 190. The method of claim 176, wherein said Bunyaviridae isselected from the group consisting of Rift Valley fever virus, La Crossevirus and Andes virus.
 191. The method of claim 176, wherein saidPoxviridae is selected from the vaccinia virus and monkeypox virus. 192.The method of claim 176, wherein said Arenaviridae is selected from thegroup consisting of Tacaribe virus and lymphocytic choriomeningitisvirus.
 193. The method of claim 176, wherein said Picornaviridae isEncephalomyocarditis virus.
 194. The method of claim 176, wherein saidTogaviridae is Sindbis virus.
 195. The method of claim 176, wherein saidFlaviviridae is Dengue virus.
 196. The method of claim 176, wherein theviral infection is caused by a Filoviridae and said Filoviridae is Ebolavirus.
 197. The method of claim 176, wherein said Orthomyxoviridae is aninfluenza virus.
 198. The method of claim 197, wherein said influenzavirus is H1N1 virus.
 199. The method of claim 176, wherein saidRetroviridae is a Human Immunodeficiency virus.
 200. The method of claim176, which further comprises co-administration of at least one agentselected from the group consisting of antiviral agent, vaccine, andinterferon.
 201. The method of claim 200, wherein said antiviral agentis Ribavirin.
 202. The method of claim 200, wherein said antiviral agentis cidofovir.
 203. The method of claim 200, wherein said interferon ispegylated.
 204. The method of claim 176, wherein said bacterialinfection is caused by a bacteria family selected from the groupconsisting of Chlamydiaceae and Coxiellaceae.
 205. The method of claim204, wherein said Chlamydiaceae is selected from the group consisting ofChlamydophila caviae and Chlamydophila muridarum.
 206. The method ofclaim 204, wherein said Coxiellaceae is Coxiella burnetti.
 207. Themethod of claim 176, wherein the compound of Formula II isN-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]-2-chloro-benzamide.208. The method of claim 207, wherein the viral infection is Ebolavirus.